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Abstract
In type 1 diabetes (T1D), an autoimmune disease, autoantibodies are preferentially
directed against proteins associated with Golgi and post-Golgi secretory vesicles,
including insulin secretory granules and synaptic-like microvesicles. Thus, the study
of β-cell autoantigens with yet unknown function may provide novel insight into the
secretory machinery of β-cells and lead to the discovery of novel pathways.
Islet cell autoantigen of 69 kDa (ICA69) is a T1D autoantigen. It is a cytoso-
lic protein of still unknown function. An impairment in neurotransmitter release
upon mutation of its homologue in C. elegans suggests, however, an involvement
of ICA69 in neurosecretion. Interestingly, ICA69 contains a BAR domain, present
in several proteins involved in intracellular transport. The BAR domain functions
as a dimerization motif, provides a general binding interface for different types of
GTPases, and is a membrane binding/bending module. Its presence in ICA69 is
a further hint supporting the putative involvement of ICA69 in intracellular mem-
brane trafficking.
The first part of this thesis was concerned with the characterization of ICA69, and
the elucidation of its role in membrane traffic in pancreatic β-cells. ICA69 was shown
to be enriched in the perinuclear region, where also markers of the Golgi region are
found. ICA69 was shown to interact with several membrane lipids, preferentially
with PI(4)P, enriched on the Golgi complex. During the course of this thesis a
combination of biochemical and imaging techniques were applied to investigate the
interaction between ICA69 and Rab2, a small GTPase associated with the interme-
diate compartment and involved in the trafficking between the ER and the Golgi
complex. ICA69 was shown to co-immunoprecipitate with Rab2 from INS-1 cells ex-
tracts. GST-pull down assays demonstrated that this interaction is GTP-dependent.
Furthermore, confocal microscopy indicated that ICA69 and Rab2 extensively colo-
calize in particulate structures throughout the cytoplasm. Immunocytochemistry
and subcellular fractionation experiments suggested that Rab2 recruits ICA69 to
membranes. Functional studies indicated that ICA69 over-expression in INS-1 cells
has effects that resemble, and in some cases amplify those observed upon Rab2
over-expression. Specifically, it impairs the trafficking between ER and Golgi, mea-
sured through the appearance and the conversion of the pro-form of ICA512 in
the mature form of the protein. Moreover, it correlates with a redistribution of
the β-COP subunit of the coatomer, participating in the early secretory pathway,
between membrane-bound compartments and the cytosol and it reduces stimulated
insulin secretion. The data reported in this thesis conclusively point to ICA69 as a
novel Rab2 effector, and may therefore contribute to the elucidation the yet poorly
understood mechanism of action of Rab2 in the secretory pathway.
The second part of the thesis was devoted to the study of an ICA69 paralogue gene,
called ICA69-RP. Similarly to ICA69, ICA69-RP mRNA was shown to be primarily
present in tissues such as brain and pancreatic islets, showing the expression pattern
of a gene preferentially expressed in neuroendocrine cells. Unlike ICA69, however,
and similar to other genes associated with the secretory machinery of β-cells, ICA69-
RP appeared to be glucose regulated, as shown by a 1.55 fold increase in mRNA
levels upon stimulation of the cells with 25 mM glucose for two hours. Glucose stim-
ulation of β-cells prompts the activation of post-transcripional mechanisms which
quickly up-regulate the expression of secretory granule genes and consequently re-
new granule stores. The increased expression of ICA69-RP upon glucose stimulation
of cells may be part of this process. Unfortunately, all attempts to elucidate the
intracellular localization of endogenous ICA69-RP failed, and it was not possible
to obtain significant insights about its localization by over-expressing a fusion pro-
tein between ICA69-RP and GFP. Unlike other paralogues containing the BAR
domain, such as amphiphysin 1 and 2 or Rvs167p and Rvs161p, ICA69 and ICA69-
RP were shown not to form heterodimers. Furthermore, ICA69-RP did not show
any interaction with Rab2 or Rab1, involved in the anterograde transport between
ER and Golgi. Thus, its physiological role remains to be investigated.
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1.1 The intracellular traffic
Eukaryotic cells have, if compared with prokaryotic cells, an elaborate compartmentalization of
their cytoplasm reached through the evolution of distinct membrane-enclosed compartments,
or organelles. Each organelle contains a characteristic set of enzymes and other specialized
molecules which define the organelle’s structural and functional properties. Thirty years ago, the
work of G. Palade (1) and C. de Duve (2) on protein secretion established that newly synthesized
secretory proteins pass through a series of organelles, including the endoplasmic reticulum (ER),
the Golgi complex and the secretory granules, on their way to the extracellular space, where
they are released (Fig. 1.1). It was found that proteins destined for residence at the plasma
membrane, within endosomes or lysosomes, share the early stations with the secretory proteins.
Also carbohydrates and lipids follow similar routes. The molecular mechanism that underlies
vesicular transport was subsequently investigated by R. Schekman through the isolation in yeast
of secretion mutants (3) and by J. Rothman through a cell-free biochemical approach (4).
The transport between organelles involves the dynamic exchange of lipids and proteins.
This membrane traffic occurs along highly organized directional routes and preserves membrane
composition, protein topology and the biochemical and morphologic features of the different
organelles.
1.1.1 Vesicular carriers
The observation that secretory proteins are often found within small (60-100 nm), membrane-
enclosed vesicles, interspersed among the major organelles of the pathway inspired the “vesicular
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Figure 1.1: Intracellular pathways
Schematical representation of the organelles taking part in the secretory, endocytic and lyso-
somal pathways. Arrows indicate the transport steps; the yellow indicates clathrin coats, the
red and the blue indicate COPI and COPII coats, respectively. Other coats exist, though not
represented in the figure. Reproduced from (5).
transport hypothesis”, schematically illustrated in Fig. 1.2 A. This hypothesis states that the
transfer of cargo between different compartments of the secretory pathway is mediated by vesi-
cles (5).Traffic proceeds through several steps, collectively referred to as anterograde transport,
and includes the formation of vesicles at a donor compartment (budding) and their targeting
and subsequent fusion to a specific acceptor compartment. As soon as the carrier reaches the
final destination, it fuses with the acceptor compartment and lumenal proteins (cargo) are re-
leased. At this step, the carrier returns to the donor compartment to be recycled for a new
cycle of transport, allowing the retrieval of escaped resident proteins back to the corresponding
compartment (retrograde transport)(6). This process has in addition been suggested to play a
role in quality control and concentration of secretory cargo (7). Retrograde transport is also
hypothesized to occur mainly by vesicular transport (8; 9).
1.1.2 Tubular carriers
Until a decade ago vesicles were believed to be the only carriers mediating intracellular trans-
port. However, recent evidence suggest the existence of carriers that are larger and more
2
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A
B
Figure 1.2: Vesicular and tubular carriers
In addition to vesicles (A), large and pleiomorphic carriers (PCGs) moving along microtubule
tracks (B). PCGs appear to be responsible the bulk of the secretory transport between distant
compartments. Reproduced from (10).
pleiomorphic than conventional vesicles (10; 11). The formation of these large pleiomorphic
carriers (LPCs) is illustrated in Fig. 1.2 B. Ultrastructural studies have shown the existence
of a network of tubules in the cis-Golgi area (12). Imaging of the transport of cargo pro-
teins tagged with the green fluorescent protein (GFP) has indicated a tubule-mediated export
from the ER to the Golgi and from the Golgi to the plasma membrane (13). In the endocytic
pathway, tubules emerge from the early endosomes and participate in recycling to the plasma
membrane (14). LPCs have interconnected tubular and saccular components, varying in size
and shape from 100-200 nm containers to several microns long tubules or saccules with diameter
of ∼ 1µm.
1.2 Components of the secretory pathway
1.2.1 Endoplasmic Reticulum
The endoplasmic reticulum (ER) is the starting point of the secretory pathway. It is the largest
intracellular compartment, with an extensive array of interconnecting tubules and cisternae
that extend throughout the cell including the nuclear envelope. ER membranes are differ-
entiated into smooth and rough regions (SER and RER, respectively) depending on whether
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ribosomes are associated with their cytoplasmic surfaces. The SER is the site of lipid biosyn-
thesis, detoxification and storage of calcium, whereas the RER is the entry site of proteins in
the secretory pathway.
Nascent polypeptide chains are recognized by a protein complex called Signal Recognition
Particle (SRP) that delays transcripts translation and docks protein synthesizing ribosomes to
ER membranes (15). Following the docking step, polypeptides translation on membrane bound
ribosomes is continued, accompanied by translocation into the ER lumen by the Sec61 complex
(16). In rare cases the translocation into the ER lumens occurs post-translationally. This is
the case, for example, for C-tail anchored proteins, such as the SNARE proteins, which do not
contain a signal peptide and are probably integrated in the membrane by a different mechanism
(17).
Upon insertion into the ER, newly synthesized proteins encounter lumenal chaperones whose
role is to facilitate folding reactions necessary for protein maturation and oligomerization. Be-
cause only properly folded and assembled proteins are exported towards the Golgi, the ER plays
an important quality control role in protein transport (18). Additionally, in in the ER lumen,
most of the proteins are N-glycosilated by addition of a precursor oligosaccharide containing 14
sugars (19) and some of them acquire a covalently attached glycosylphoshatidylinositol (GPI)
anchor.
Protein export from the ER takes place in specialized regions of the ER, devoid of ribosomes,
called ER exit sites (ERES) (20). These are highly organized membrane domains (1-2 µm in
diameter) adjacent to the pre-Golgi intermediates.
1.2.2 ER-Golgi intermediate compartment
The ER-Golgi intermediate compartment (ERGIC or IC)1 is a complex membrane system
between the ER and the Golgi complex (21). It is also sometimes referred to as vesicular-
tubular clusters (VTCs) (22) or pre-Golgi intermediates (23) and consists of a large convoluted
mass of tubules and vesicles individually 50 nm in diameter with an average diameter for the
cluster of 0.4 microns (24). The ERGIC is enriched in the 53 kDa membrane protein ERGIC53
and the protein composition of its membranes differs from that of ER and Golgi membranes (25).
Since its identification it has been matter of debate whether the ERGIC is a specialized domain
of the ER (26), or of the Golgi complex (27), or a transient structure composed of transport
1The ERGIC is absent in S. cerevisiae. Despite yeast and mammals sharing the same secretory pathway,
mammalian cells show a greater morphological complexity of the secretory pathway compared with yeast.
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vehicles for protein delivery to the Golgi complex (28), or a distinct organelle separated from
the ER and the Golgi complex (29).
The ERGIC is the first sorting station for anterograde and retrograde protein traffic, and it
also contributes to the concentration, folding and quality control of the secretory cargo (30).
1.2.3 Golgi complex
In animal cells the Golgi complex (or Golgi apparatus) consists of a collection of flattened,
membrane-enclosed cisternae, that are interconnected by tubules, and are clustered near the
nucleus and close to the centrosome at the minus ends of microtubules. It is morphologically
and functionally polarized, with a cis entry face and a trans exit face. The Golgi complex
is the site where cargo proteins “mature”. Modifications such as oligosaccharide remodeling,
proteolytic cleavage, phosphorylation, or sulfation take place, while proteins transit through
the cisternae before vesicle packaging and transport to the final destination (31).
Although the Golgi complex has been known for over a century, key issues regarding this
organelle have remained controversial. Regarding its biogenesis two different theories have been
proposed: the Golgi complex could originate by the self-organization of components as they are
exported from the ER (32), or it could be an autonomous organelle that forms using a persistent
matrix (33). Another open issue is the modality of cargo movement through the Golgi. In the
past it has been postulated that forward transport of cargo through cisternae may occur fol-
lowing two possible models: cisternal anterograde vesicle transport or maturation, respectively.
Evidence in favour of the first model go back to the identification, through the Golgi stacks,
of membrane vesicles containing the cargo vesicular stomatitis virus (VSV)-encoded G protein
(34). However, studies on large molecules progression through the Golgi, such as procollagen
(35; 36), favored the now more credited maturation model. Nowadays most of the investigators
believe that both mechanisms play an important role in directing traffic through the Golgi (37).
Yet, the understanding of the Golgi apparatus remains largely incomplete. There is not
a definite model that explains how cisternae are connected, how many types of vesicles are
present and how the shape and the function of the cisternae are maintained.
1.2.4 Trans-Golgi network
The compartment sorting cargo for exiting from the Golgi was defined as trans-Golgi network
(TGN) by G. Griffiths and K. Simons (38). It has also been referred to as the trans-Golgi
reticulum (TGR) (39). The TGN is a collection of the last trans-cisterna of the Golgi and
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a network of large, pleiomorphic, tubular formations and vesicles that extends from it (the
network of these carriers is called post-Golgi carriers - PGCs). In the TGN, the proteins
and lipids destined for distinct subcellular compartments are sorted and packaged into specific
transport carriers (40). At least three transport pathways originate from the TGN: pathway
to the lysosomal compartment and two (constitutive and regulated) directed towards the cell
surface.
After detaching from the Golgi complex, PGCs undergo dramatic shape changes, including
extension, retraction and bifurcation (41).
1.3 Vesicle budding and fusion
Figure 1.3: The vesicular transport hypothesis
The formation of a coated vesicle involves the recruitment of coat proteins from the cytosol, the
budding of the vesicle from the “donor” compartment and the scission of the vesicle. Follow by
the uncoating of the vesicle (and consequent recycling of coat components), the tethering, the
docking and the fusion of the vesicle with the specific “acceptor” compartment. Reproduced
from (10).
According to the “vesicular transport hypothesis” discussed above and illustrated schemat-
ically in Fig. 1.3, the formation of a vesicle follows a prescribed course of events. Coat compo-
nents are recruited from the cytosol to the “donor” compartments. These initiate and propagate
the assembly of a coat, determine the invagination of the underlying membrane (budding) and
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at the same time the sorting of the cargo molecules and their inclusion in the budding vesicles.
When the formation of the coat ends, the vesicle bud separates from the “donor” compartment
by scission of the neck connecting the invaginated membrane to the donor surface. Afterwards,
by a process of uncoating, the coat components are released (and recycled). The vesicle moves
then to the “acceptor” compartment, probably on cytoskeletal tracks. Follow the tethering,
docking, priming and fusion of the vesicle to the “acceptor” compartment. These final steps are
directed by Rab proteins, tethering factors and SNARE proteins. Finally the cargo is released
to its final destination (5).
1.3.1 Formation of coated vesicles
Although several kind of of carriers have been identified, some of which have a coat seen
by electron microscopy, vesicles clearly identifiable by their coat components (clathrin-coated,
COPI-coated and COPII-coated vesicles) are the best studied. The attention here is focused
on those coats which have a recognized role in the secretory pathway.
1.3.1.1 Clathrin-coated vesicles
Clathrin-coated vesicles (CCV) were the first coated vesicles to be discovered (42) and are
considerably more complex than the other coated vesicles regarding the network of proteins
involved in their formation. Initially they were assumed to participate in most, if not all,
vesicular transport steps within the cell. However, as demonstrated in later studies, the function
of these coats is restricted to the receptor-mediated endocytosis, the trafficking from the TGN
to the late endosomes and the remodeling of immature secretory granules.
Clathrin is the main constituent of the clathrin-coated vesicles. It is composed of three heavy
chains and three light chains that together form a structure called triskelion (42). Clathrin
triskelions assemble into a basket-like framework of hexagons and pentagons to form coated
pits, which constitute the scaffold of the budding vesicle.
A second major component of the clathrin-coated vesicles is an adaptor protein complex
(AP), described in section 1.3.2 on page 14. Focusing on the most characterized adaptors AP-1
and AP-2, the formation of the coated vesicle, as outlined in Fig. 1.4, is initiated by the recruit-
ment of the AP to the membrane. Synaptotagmin, a calcium sensor, and phosphatidylinositol-
4,5-bisphosphate (PI(4, 5)P2) are probably involved in the binding of AP-2 to the plasma mem-
brane. ADP-ribosylation factors (ARFs) (see section 1.3.3 on page 15), ARF1 and ARF3, in
particular, are involved in the recruitment of AP-1 to Golgi membranes (43; 44). APs have
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many functions, such as the recruitment of clathrin, the selection of specific cargo to be incor-
porated in the nascent vesicle, and the binding of accessory factors involved in the formation
of the vesicle. Specific transmembrane proteins and their lumenal cargo molecules become con-
centrated in the budding vesicle. Some receptors, such as the low density lipoprotein receptor
are constitutively included in the pits (45), while some others, like the insulin receptor, are
included in the pits only in response to ligand (46). Also Rab and SNARE proteins, involved in
the later steps of targeting and fusion of the vesicle to the acceptor compartment, are recruited
into the vesicle.
Figure 1.4: Formation of clathrin-coated vesicles
Coat assembly is initiated by recruitment of AP complexes on the membrane which subsequently
recruit other components, including clathrin. The polymerization of clathrin leads to membrane
deformation. The pinching off of the vesicle is caused by dynamin. Modified from (44).
Several accessory proteins play a role in facilitating and regulating vesicle formation. For ex-
ample amphiphysin, which binds clathrin, AP-2 and dynamin (regulating its GTPase activity),
and can contribute to membrane bending with its BAR domain (as described in section 1.3.8
on page 23) (47; 48). Epsin contributes to membrane bending by inserting its ENTH (epsin
amino terminal homology) domain into the membrane (49). Endophillin, which induces mem-
brane bending via its BAR domain (50). Synaptojanin, with its phosphoinositide phosphatase
activity plays a role, through removal of a phosphate from PI(4, 5)P2, in the disassembly of the
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clathrin coat by decreasing the affinity of AP-2 for the vesicle (51).
The final fission of the vesicles is mediated by the GTPase dynamin, which can self assemble
in spirals at the vesicle neck (52). Its precise mechanism of action remains unclear. Several
hypotheses regarding the role of dynamin have been proposed. Following GTP hydrolysis the
dynamin ring could contract leading to the fission of the vesicle (“pinchase” model). Alter-
natively, dynamin could, in its GTP-bound state, recruit effectors (not yet identified) which
are the actual “pinchases” (53). Or, according to recent reports, dynamin could act as a
mechanoenzyme causing fission of the vesicle if membrane tension is generated by other factors,
maybe by the actin cytoskeleton (54) . After the fission the clathrin coat is removed. The heat
shock protein Hsc70 and auxillin cause the uncoating of the vesicle, through an ATP-dependent
reaction.
Some experiments indicate the presence of clathrin and the adaptors GGA1 and AP-1 in
highly pleiomorphic (vesiculo-tubulo)-intermediates in the TGN (55). This would constitute a
coat partially different from the classical clathrin coats.
Recently a new type of clathrin coats has been observed in association with pre-melanosomes
and with early endosomes, and whose understanding requires further investigations. They
contain 2 layers of clathrin, and instead of adaptors contain the protein Hrs, which binds to
clathrin and to ubiquitinylated membrane proteins (10).
1.3.1.2 COPI vesicles
COPI-coated vesicles (also referred to as coatomer-coated vesicles) were originally identified
through the use of a cell-free assay to study the transport between the ER and Golgi as vesicles
with a diameter of 75 nm derived from the Golgi complex (56). The function of COPI-coated
vesicles is still a matter of ongoing debate. What is known is that they have a clear function
in the retrograde transport from the ERGIC and from the Golgi complex to the ER. Addition-
ally, they could play a role in anterograde transport from the ERGIC to the Golgi complex
and within the cisternae of the Golgi (Fig. 1.5). Microinjection of antibodies against COPI
components, indeed, also blocks anterograde ER to Golgi transport (57). This inhibition of the
anterograde transport could be indirect. Because given that the anterograde and retrograde
pathway are tightly coupled, continued anterograde transport requires a functional recycling of
cargo receptor and other factors back to the ER.
However an increasing number of studies have pointed to a role of COPI-coated vesicles in
anterograde transport. COPI-coated vesicles, for example, mediate the transport of proteins
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Figure 1.5: Involvement of COPI vesicles both in anterograde and retrograde ER-
to-Golgi transport
Anterograde transport from ER to the Intermediate compartment occurs through COPII-coated
vesicles. As described in the text, recent results suggest an involvement of COPI-coated vesicles
in both the retrograde transport (back to the ER) as well as the anterograde transport, from
the Intermediate compartment to the Golgi. Modified from (58).
through the Golgi stacks. Two distinct populations of COPI vesicles which contain either
anterograde or retrograde cargo have been identified. Furthermore, live-imaging has revealed
the existence of COPI coated carriers moving the cargo protein VSV-G to the Golgi (30; 41; 59;
60). Several mechanisms have been proposed to explain the distinction between anterograde
and retrograde traffic mediated from COPI vesicles budding from ERGIC. Differential and
ARF-dependent sorting of proteins by COPI, or alternatively involvement of different ARF
isoforms, or molecular variations of the COPI coat. Also, differential Rab-dependent sorting
through different effectors that the two Rabs associated with the ERGIC (Rab1 and Rab2)1
might activate effectors, which in turn could involve different tethering complexes (30).
The COPI coatomer (700 kDa) is a cytoplasmic complex of seven protein subunits: α, β,
β′, γ, δ,  and ζ. COPI vesicles efficiently incorporate specific proteins to be transported.
γ-COP seems to be the component responsible for cargo recognition, done on the basis of
the presence, on cargo proteins, of di-lysin motifs KKXX or KXKXX (K is lysine, X is any
amino acid) in their cytosolic domain (or in the cytosolic domain of the receptor that mediate
1Rab1 is involved in the anterograde transport between the ER and the Golgi complex, whereas Rab2 is
involved in the retrograde transport (61). Evidence point also to the involvement of Rab2 in the anterograde
transport from the intermediate compartment to the Golgi (30; 62; 63).
10
1.3 Vesicle budding and fusion
Figure 1.6: Formation of COPI-coated vesicles
Coat assembly is initiated by ARF1-GTP which recruits the COPI coatomer. Membrane defor-
mation occurs during coat recruiting. When the coat is complete the vesicle buds. Reproduced
from (44).
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their transport). The initial event in the formation of a COPI-coated vesicle, as outlined in
Fig. 1.6, is the activation and subsequent binding to the membrane of ARF1 (ARF proteins
are described below in section 1.3.3 on page 15) . ARNO3, the GEF implied in this activation,
promotes the GDP-GTP exchange in ARF1, which changes its conformation and, by exposing
its myristoyl group, binds to the membrane. Activated ARF1 recruits the coatomer en bloc.
The polymerization of the coat and the membrane deformation into buds first and vesicles follow
afterwards (44; 64). Additional, though not essential proteins such as p24, might be involved
in the recruitment of COPI coatomers to membrane (65). The energy for the fission reaction
of the vesicle comes from the hydrolysis of GTP to GDP and from the mechanical curvature of
the membrane induced by the coatomer, and does not involve any “pinchase”, contrary to the
fission of clathrin coated vesicles.
Afterwards ARF-GAP1, and possibly other members of the same family, induce GTP hy-
drolysis in ARF1-GTP and an uncoating of the vesicle. Some evidence suggest that ARF-GAPs
might be involved in the sorting of some cargo, namely the KDEL receptor, and the v-SNAREs
(involved in the targeting and fusion steps of the vesicle with the acceptor membrane) (66).
1.3.1.3 COPII vesicles
COPII-coated vesicles were originally identified in S. cerevisiae through the analysis of sec-
mutants with a defective secretion (67) and the use of a cell-free assay to study the transport
between the ER and Golgi (68). They are approximately 60-65 nm in diameter and mediate
the export of newly synthesized proteins from the ER to the ERGIC.
The formation of COPII-coated vesicles is outlined in Fig. 1.7. Vesicle budding occurs at
the ER exit sites and is initiated by Sec12p, a GEF for Sar1p of the ARF family (see section
1.3.3 on page 15). Sec12p may act in conjunction with Sec16p, a putative scaffold protein.
The active form of Sar1p binds to the ER membranes and recruits first the Sec23p/Sec24p
complex and then afterwards the Sec13p/Sec31p complex, which induces coat polymerization
and membrane deformation into buds and then vesicles (10; 69).
The Sec24p subunit is involved in the recruitment of the cargo in the vesicles (70). The
sorting signals recognized by the COPII coat are found in the cytosolic domain of transmem-
brane cargo proteins. Some of them are di-hydrophobic motifs, such as di-phenylalanine (found
in ERGIC53) whereas others are di-acidic motifs, such as Asp-X-Glu (found in the VSV-G
protein and in the potassium channel proteins, with X standing for an arbitrary aminoacid)
(60). Certain soluble cargo molecules depend on receptor-like proteins for efficient ER export,
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Figure 1.7: Formation of COPII-coated vesicles
Coat assembly is initiated by Sar1p-GTP which recruit sequentially the Sar23p/Sec24p and
the Sec13p/Sec31p complexes. Membrane deformation occurs during coat recruiting. Upon
completion of the coat the vesicle buds. Reproduced from (44).
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although signals that direct soluble cargo into ER-derived vesicles are not well understood. The
Sec23p subunits binds specific SNAREs involved in the docking and fusion steps of the vesicle
with the acceptor membrane. It also acts as a GAP for Sar1p. Sar1p in the GDP-bound form
is released, leading to uncoating of the vesicle.
As for the COPI vesicles, the energy for the fission reaction of the vesicle comes from the
hydrolysis of GTP to GDP and from the mechanical curvature of the membrane induced by
the coat.
1.3.2 Adaptor complexes
At least four major classes of AP complexes (APs) exist (71): AP-1, which is involved in the
constitutive secretory pathway and in the TGN-endosomal-lysosomal pathway; AP2, which is
required in clathrin-mediated endocytosis; AP-3, which binds clathrin but does not require it
for function and plays a key role in melanosome sorting in melanocytes, in synaptic vesicle
biogenesis in neurons, and in granule biogenesis in platelets (72); and AP-4, which does not
bind to clathrin, but is associated to non-clathrin coated vesicles in the TGN area (73). The
Golgi-localized, γ-ear-containing, ARF-binding proteins (GGAs) belongs to the same family,
moves along the same AP-1 route, and may share some of its functions (74). A different type of
adaptor proteins are the arrestins, which recruit G protein-coupled receptors to clathrin coated
vesicles at the plasma membrane (75).
APs are heterotetrameric complexes formed by two large subunits (β associated to µ in
AP-1, to α in AP-2, to γ in AP-3, and to  in AP-4), a medium µ (µ1 − µ4) subunit, and
a small σ (σ1 − σ4) subunit. The core region, the “head”, is flanked by two “ears”, mainly
composed by the large subunits (76). The GGAs are monomers that contain all the previously
described functional domains in the same protein.
The function of adaptors has already been addressed in the section regarding the formation
of clathrin-coated vesicles (section 1.3.1.1 on page 7).
1.3.3 ARF proteins
The ARF family of proteins belong to the Ras superfamily of small GTPases. Like the other
members of the superfamily, they cycle between an active GTP-bound form and an inactive
GDP-bound form. ARF proteins function depends on several classes of proteins: guanine
nucleotide exchange factors (GEFs) which promote the formation of ARF-GTP, and GTPase-
activating proteins (GAPs) which induce GTP hydrolysis. All ARF proteins are myristoilated,
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and this is important for their binding to membranes (77). ARF proteins have many effec-
tors. The involvement of different ARFs in specific processes is achieved in an effector- and
compartment-specific fashion (78).
Six different ARF proteins (ARF1-ARF6) have been isolated in mammals. They regulate the
assembly of coats on budding vesicles along the secretory and the endocytic pathway, activate
lipid-modifying enzymes and are involved in actin polymerization as well as in phagocytosis
(79). Sar1p belongs to the ARF family of proteins and is involved in the formation of COPII
vesicles (80). Contrary to the ARFs, Sar1p is not myristoilated. Also the so-called ARF-
like (ARL) proteins belong to the same family. They do however appear to have distinct roles
compared to the other ARFs (e.g. Arl1 is involved in the tethering of endosomes derived vesicles
to the TGN and Arl2 is involved in the folding of β-tubulin) (81).
1.3.4 Vesicle transport and the cytoskeleton
The cytoskeleton plays a clear role in the transport and the positioning of membrane-enclosed
organelles (82). In non-polarized cells the minus ends of microtubules are located near the center
of the cell, at the centrosomes, with the plus ends extending to the cell periphery. In polarized
cells such as epithelial cells and neurons, which have more than one distinct plasma membrane
domain, to which different types of vesicles must be directed, the organization of microtubules is
more complex. For example, in epithelial cells the minus ends of the microtubules are localized
at the apical surface, whereas the plus ends are at the basolateral surface (24). In neurons,
in the axons the plus ends of the microtubules are pointed towards the nerve termini, and the
minus ends towards the cell body, whereas in the dendrites the microtubules are found in both
orientations (82). Actin microfilaments are concentrated in a cortex, just beneath the plasma
membrane, but are also found dispersed throughout the cell.
As pointed out in Fig. 1.8, in non-polarized cells, ER elements (and endosomes, though not
indicated in the figure) are dispersed along microtubules towards the plus ends pointed at the cell
periphery, with the Golgi complex (plus late endosomes and lysosomes) clustered at the minus
ends of the microtubule, at the center of the cell (84). The microtubule-dependent localization
of organelles within the cytoplasm is confirmed by experiments in which the treatment of cells
with colchicine or nocodazole, which depolimerize microtubules, causes ER collapse to the center
of the cell as well as Golgi fragmentation and dispersion throughout the cytoplasm (85).
It has been proposed that the long-range vesicle transport takes place along microtubules
using the plus-end directed motor kinesin (83) (or a member of the superfamily of kinesin related
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Figure 1.8: Vesicle transport and cytoskeleton
The microtubule-dependent distribution of ER, intermediate compartment and Golgi complex
within the cell. Microtubules provide a scaffold for the plus-end directed extensions of the ER
and the minus-end anchored Golgi cisternae. Anterograde transport (circles), dynein-directed
and retrograde transport (triangles), kinesin-directed are also indicated. Modified from (83).
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proteins (KRPs or KIFs)) and the minus-end directed motor dynein (cytoplasmic dynein, in
particular). The short range vesicle transport takes place on actin filaments by myosin motors
(82). The molecular mechanism by which kinesin is recruited to membranes is not clear. It
is known that several kinesins directly interact with specific cargoes (86). Some evidence,
however, point to an involvement of Rab proteins in this process (with no clear consensus
emerging) (30; 87), an aspect that is investigated further in section 1.3.5 on page 17). The
mechanism by which dynein binds to membranes is better understood. It is known that dynein
attaches to the membrane indirectly by interacting with dynactin, which is a multi-subunit
complex that binds to integral membrane proteins in the vesicle through its spectrin/ankyrin
skeleton (24).
1.3.5 Rab proteins and membrane tethering
The final steps in vesicle-mediated transport between organelles are: the targeting of the vesicles
to the appropriate acceptor compartment; the initial and reversible interaction between the
membranes of the vesicle and the acceptor compartment (tethering); the docking of the vesicle
to the acceptor compartment, which leads to a more tight interaction between their membranes;
the priming of the vesicle, which activate membranes for the subsequent fision; and finally the
fusion of the vesicle with the acceptor compartment.
The Rab (Ras-related proteins in brain) family of proteins belongs to the Ras superfamily of
small GTPases and plays a key role in (but not only) the tethering of the vesicles to the acceptor
compartment, providing the necessary specificity to this process. Rab proteins are initially
synthesized as soluble proteins in the cytosol, and post-translationally modified by prenilation,
meaning the addition of usually two but in some cases one geranyl-geranyl group. To be more
detailed, the newly synthesized Rab proteins are first recognized by a Rab escort protein (REP),
which presents them to a Rab geranyl-geranyl transferase and escorts the already prenilated
Rab proteins to their target membrane. As previously described for the small GTPases ARFs
(see section 1.3.3 on page 15), Rab proteins cycle between an active GTP-bound form and
an inactive GDP-bound form, the switch between the two forms being controlled by guanine
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). After performing
their function, Rab proteins are extracted from membranes by a Rab GDP dissociation inhibitor
(GDI), and remain in the cytosol until the next cycle (77). More than 60 mammalian Rab
proteins have been identified, each one with a specific intracellular localization, as illustrated
in Fig. 1.9.
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Figure 1.9: Subcellular localization of Rab proteins
Rab proteins show a precise distribution within the cell: some of them are present in all cell
types, while others (e.g. Rab3, Rab27 and Rab17) are cell specific. EC: epithelial cell; M:
melanosomes, T: T-cell granules; SG: secretory granule; SV: synaptic vesicle; MTOC: centro-
some; CCP and CCV: clathrin-coated pits and vesicles, respectively. Reproduced from (88).
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Rab effectors are defined as proteins that interact with a GTP-bound Rab, but not with
a GDP-bound Rab, and transduce the signal of the Rab protein in the transport mechanism
(88). Many Rab effectors have been identified and new ones are continuing to be discovered,
providing the basis of the understanding of how Rab proteins regulate and coordinate diverse
processes like vesicle budding, transport along the cytoskeleton, docking and fusion of vesicles
to the acceptor compartment (89), and interact with signaling pathways to regulate membrane
traffic spatially and temporally (77).
Focusing on the docking and fusion of vesicles to the acceptor compartment, Rab proteins
facilitate and regulate the rate of vesicle docking and the matching of cognate SNAREs: this is
accomplished through the recruitment, by the GTP-bound Rab, of specific docking factors from
the cytosol, which remove putative inhibitor factors (SNARE protectors, that block SNARE
pairing at all times) and facilitate the SNAREs pairing, conferring also additional specificity to
the identification between the vesicle and the appropriate acceptor compartment (90). Several
macromolecular complexes have been identified that function as docking factors: the Exocyst,
originally identified in yeast (91), and present also in mammals (92), required for docking of
vesicles to the plasma membrane; the Rabaptin-5 complex (93), important for Rab5-dependent
early endosome fusion; the TRAPP (transport protein particle) complex, required for ER-to-
Golgi transport in yeast (94).
1.3.6 Other Rab functions
Rab proteins are also required for vesicle budding. It has been hypothesized that vesicle forma-
tion is regulated such that budding only occurs if the vesicle contains both Rab and SNARE
proteins necessary for docking and fusion (90). However, recent results suggest that Rab pro-
teins play an active role in vesicle budding as detailed in the following. Expression of a dominant
negative form Rab1 (Rab1S25N , with a lower affinity for GTP than normal and almost uniquely
present in its GDP-bound form) inhibits export from the ER to the Golgi (95). In the inter-
mediate compartment Rab2, through the protein kinase C PKCι/λ, promotes the recruitment
of COPI to generate retrograde transport of vesicles (63). A dominant negative form of Rab9,
Rab9S21N , strongly inhibits mannose-6-phosfate receptor (MPR) recycling from endosomes to
the trans-Golgi network (96). On the plasma membrane, Rab5 seems to be involved in ligand
sequestration in the clathrin-coated pits (97).
As discussed in section 1.3.4 on page 15, Rab proteins are also involved in controlling the
recruitment of motor proteins on defined compartments. The first description of a Rab protein
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directly coupling to a motor protein was for the Golgi-associated Rab6, which binds Rabkinesin-
6 (RB6K), a kinesin-like protein (98). Since then, a growing number of similar examples have
been reported in the literature. For example, BicD1 and BicD2, can bind Rab6 and dynactin
(which in turn binds dynein) (99); Rab4, in the GTP bound form, binds KIF3B, a kinesin-2
family member (100); and Rab5 interacts with the dynactin/dynein complex (101), as well as
with KIF16B, a kinesin-like protein (102; 103).
1.3.7 SNARE protein and vesicle fusion
The SNARE proteins (SNAREs or SNAP receptors) play a central role in the docking and
especially in the fusion processes of the vesicle with the acceptor compartment (104). SNAREs
are a superfamily of small proteins originally identified as plasma membrane receptors for α-
SNAP (soluble NSF association factor), which binds NSF (N-ethylmaleimide-Sensitive-Factor),
required for membrane fusion, to membranes. These proteins had previously been implied in
the binding of synaptic vesicles to the plasma membrane (105; 106). SNAREs are small C-
tail anchored proteins (C-terminally anchored transmembrane proteins, with their N-terminal
domain facing the cytosol, as described in section 1.2.1 on page 3) of around 100-300 aminoacids
in length. They share a common homologous sequence of 60 residues, known as SNARE motif,
involved in the formation of a complex with a coiled-coil structure between SNAREs on opposite
membranes (three SNAREs, SNAP-23, SNAP-25 and SNAP-29, contain two tandem SNARE
motifs) (107). SNAREs are structurally classified as Q-SNAREs and R-SNAREs, depending
on the presence of a glutamine (Q) or an arginine (R) at a characteristic position within the
SNARE motif (108). In the early ’90s the SNARE hypothesis for membrane fusion, outlined in
Fig. 1.10, was proposed. According to this hypothesis every vesicle has its own v-SNARE, and
every target membrane has its own t-SNAREs. Fusion of membranes occurs when the cognate
v- and t-SNAREs engage1, in a parallel fashion (109). The complex so generated is a very
stable four-helix bundle, with one α-helix contributed by the monomeric v-SNARE and three
α- helices contributed by the oligomeric t-SNARE (107). Assembly of SNAREs in the opposing
membranes pulls the membrane close to each other, generating the energy needed to bring the
two negatively charged opposing membranes close enough, and cause the formation of a stalk
hemifusion intermediate and then the opening of a fusion pore, with fusion of the vesicle to the
acceptor compartment. Upon fusion, the SNARE complex is disassembled. NSF is an ATPase
1Despite the distinction between v- and t-SNAREs is not meaningful during the homotypic fusion of or-
ganelles, this classification remains useful. Moreover there is a rough correspondence between R- and v-SNAREs
and between Q- and t-SNAREs.
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Figure 1.10: SNAREs in membrane fusion
After the tethering and docking steps, directed from Rab proteins and their effectors, appropri-
ate SNAREs pair. The SNARE complex is formed by a monomeric v-SNARE on the vesicle and
an oligomeric t-SNARE on the “acceptor compartment”. The pairing, first loose, becomes tight
following the priming, and this results in membrane fusion and release of vesicle content. After
fusion, the SNARE complex is disassembled by NSF (recruited through α-SNAP). Modified
from (104).
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that binds the SNARE complex via an adaptor called SNAP (α-SNAP described above belongs
to this class of proteins), and generates the energy necessary to dissociate the SNARE complex
(110).
Besides NSF and SNAPs, many additional factors, which facilitate and regulate the fusion
reaction, have been identified. An important group of SNARE-interacting proteins is the SM
family (Sec1/Munc18-like proteins). These proteins play a prominent role in vesicle trafficking,
and each membrane fusion step requires a specific SM protein. Despite this, their function
remains enigmatic. Depending on the specific SM protein, they can stimulate or inhibit SNARE
complex assembly (this seems to be the case for Munc13 and Munc18 respectively), they may
confer additional specificity in the pairing of cognate SNAREs or couple the assembly of the
SNARE complex to membrane attachment, or act as chaperones for the SNAREs (110; 111).
Moreover, some evidence point to the existence of an inhibitory class of SNAREs, the i-SNAREs,
which prevent incorrect fusions from occurring. They could act by competing with either the
v-SNARE or the t-SNARE during the formation of the SNARE complex, or by binding to the
SNARE complex and prevent it from driving membrane fusion (112).
The role of Ca2+ in SNAREs-dependent membrane fusion (in exocytosis, in particular) will
be addressed later, in section 1.4.2.2 on page 32.
1.3.8 Proteins with BAR domain
Proteins carrying a BAR (bin, amphiphysin and Rvs161/167) domain are a class of cytosolic
proteins with membrane-binding and/or membrane-deforming properties, mostly involved in
intracellular transport and especially in endocytosis. The BAR domain, first solved by Peter
and coll. (48; 113), and illustrated in Fig. 1.11, is an elongated banana-shaped dimer which
can fit a curved membrane with an outer diameter of 22 nanometers (nm): each monomer (200
amino acids long) is a coiled-coil of three kinked α-helices, which give rise to a six-helix bundle
upon dimerization. Both ends and the concave surface of the dimer are positively charged,
suggesting their interaction with the negatively charged phospholipids of membranes. The
BAR domain can either bind and deform membranes (“strong” BAR domain) (114; 115) or act
only as a curvature-sensing module, sensing rather than imposing membrane curvature (“weak”
BAR domain) (116).
Some of the proteins with a BAR domain have, in addition, an N-terminal amphipatic helix
which folds upon membrane binding, causing the displacement of lipids in one leaflet. This helix
enhances the ability of these proteins to deform membranes. The combination of the N-terminal
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diameter
22 nm
Figure 1.11: Structure of the BAR domain
Ribbon representation of the antiparallel homodimer of the Drosophila BAR domain: the two
monomers are indicated in purple and green. The banana shape is generated upon dimerization
and can fit a curved membrane with an outer diameter of 22 nanometers. Modified from (117)
helix and the BAR domain is referred to as N-BAR domain. Examples of proteins carrying a
N-BAR domain are amphiphysins, BRAP1/Bin2 (breast cancer associated protein1/bridging
integrator 2), endophillins and nadrins (48). Recently it has been reported the presence, in a
family of proteins implied in the regulation of actin cytoskeleton (e.g. Toca-1 and syndaptin),
of an N-terminal module similar to the BAR domain and called F-BAR domain. This domain
corresponds to the FCH (Fes/CIP4 homology) domain followed by the CC (coiled-coil) domain
previously identified in these proteins and, as the BAR domain, is a membrane binding/bending
module (113; 118).
Some BAR proteins have additional motifs that provide further functions. These may
enhance membrane association, like the pleckstrin homology (PH) domain (oligophrenin and
centaurinβ) or the phox homology (PX) domain (sorting nexins); mediate the interaction with
other proteins, like the Src homology 3 (SH3) domain (amphiphysin and tuba); or regulate
the activity of small GTPase through GEF or GAP domains (nadrins, tuba, oligophrenin and
centaurinβ) (48).
Furthermore, some other proteins belonging to the same family interact with small GTPase
and take part in the signalling pathways from them regulated. Arfaptins, for example, bind
alternatively Arf1/Arf6 in the GTP-bound form and Rac in the GDP-bound form, and probably
mediate the cross-talk between these two GTPases (113; 118). Another example are APPL1
and APPL2 (from adaptor protein containing PH domain, PTB domain and Leucine zipper
motif) which are Rab5 effectors (119).
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1.3.9 Phosphoinisitides
Phosphatidylinositides (PIs) are important regulatory molecules involved in diverse processes
such as signal transduction, cytoskeleton remodeling, cell migration and membrane trafficking.
Phosphorylation on different positions of the inositol ring generates different isomers that are
heterogeneously distributed in the cell and, together with proteins, especially small GTPase
(described earlier in this section), provide additional specificity to the processes indicated above
(120; 121).
PIs were initially characterized as mediators of signal transduction events, through the
formation on the plasma membrane of second messengers like inositolpolyphosphate 3 (IP3),
diacylglycerol (DAG) or arachidonic acid from PtdIns4, 5P2 (PI(4,5)P2)) (122). Later it was
clarified that PIs may also act directly in signal transduction, interacting with proteins (ef-
fectors) bearing a lipid-binding domain like the pleckstrin homology (PH) domain, the FYVE
(from Fab1-YOTP-Vac1-EEA1) domain, the epsin amino terminal homology (ENTH) domain,
the phox homology (PX) domain, the C2 (for the homology with PKC) domain or the plant
homeodomain (PHD) (123). Various are the examples of the involvement of PIs in membrane
trafficking. PI(4,5)P2 is enriched in regions of the plasma membrane and promotes clathrin-
mediated endocytosis, through the recruitment of the adaptor complex AP-2 and accessory
proteins with a role in endocytosis (dynamin among them). PI(4,5)P2 is also involved in se-
cretory granule exocytosis, probably through the proteins synaptotagmins and CAPS (Ca2+
dependent activator protein for secretion) and it plays a role in rearrangement of the actin
cytoskeleton through ARF6 and the small GTPase Rho (124). Moreover, PI(4)P enriched in
the Golgi, is involved in the recruitment of AP-1 to the Golgi and is therefore important for
AP-1 dependent functions (125); and PI(3)P, enriched on the early endosomes, plays a role in
endocytic trafficking, through the interaction with Rab5 and the recruitment of proteins with
a FYVE domain, such as EEA1 (121).
1.4 Constitutive and regulated secretion
The term exocytosis indicates the fusion of a vesicle with the plasma membrane. Constitutive
exocytosis occurs in all cells, and it is required for constant delivery of newly synthesized
proteins and lipids to the cell surface. In specialized secretory cells a second pathway also
exists (regulated secretory pathway) in which soluble proteins and other substances are initially
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stored in secretory vesicles, and released only in response to a physiological signal. Fig. 1.12 is
a schematical representation of the two pathways.
Figure 1.12: Constitutive and regulated secretory pathways
The constitutive secretory pathway operates in all cells. Many soluble proteins are continuously
secreted by this pathway, which also supplies the plasma membrane with newly-syntethized
components. Specialized secretory cells also have a regulated secretory pathway, where secretion
happens only in response to appropriate stimuli. Reproduced from (58).
1.4.1 Constitutive secretion
The constitutive secretory pathway assures constant delivery of membrane proteins, receptors
and lipids from the TGN to the cell surface. Some extracellular molecules (e.g. plasma proteins,
antibodies, extracellular matrix components, lipids for the formation of the myelin sheats, etc.)
are also secreted by a constitutive secretory pathway (126). Constitutive exocytosis is observed
in non-polarized cells and in polarized cells (to which epithelial cells and neurons belong to),
that have two distinct plasma membrane domains. Epithelial cells secrete constitutively mainly
through their basal membrane. Neurons secrete constitutively trough their somato-dendritic
membrane (127). Recent findings point to the existence of multiple parallel routes in mem-
brane traffic from the TGN to the plasma membrane, even in a non-polarized cell such as a
fibroblast: an AP-1- and/or AP-4-based direct route from the TGN to the plasma membrane,
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an actin and Cdc42-dependent route, a constitutive transport (e.g. for VSV-G-containing
vesicles) to the basolateral membrane involving microtubules and the Exocyst, a constitutive
transport to the apical membrane involving Kinesin and Dynamin-2 (e.g. for influenza virus
hemoagglutinin(HA)-containing vesicles), and an AP-dependent route from the TGN to the
endosomes and from here to the plasma membrane via the recycling endosomes (e.g. for the
glucose transporter GLUT-4-containing endosomes in adipocytes) (127; 128).
As described in previous sections (1.1.1 and 1.1.2 on pages 1-3), ultrastructural studies have
lead to the widely accepted view that constitutive traffic may proceed through small (60-80 nm)
coated vesicles, or through large, pleiomorphic and highly dynamic carriers moving from the
perinuclear area to the periphery along microtubule tracks (129). It is still not clear whether
clathrin is required or not for constitutive secretion. Likely only some of the routes from the
TGN to the plasma membrane (e.g. the one through the recycling endosomes) are regulated
by clathrin and AP complexes. A possibility is the involvement of a not yet identified non-
clathrin coat on constitutive vesicles (130). Despite original data indicated the constitutive
pathway as a default pathway, for which proteins lacking any targeting information would exit
the cell constitutively (131), more recent data indicate the existence of sorting signals, although
degenerate, for constitutive secretion (127). It is not clear, however, how the active sorting of
proteins in the constitutive pathway occurs.
Since constitutive exocytosis is often presented as the opposite of regulated exocytosis, it
is widely considered as unregulated. However, constitutive exocytosis is well controlled, as
demonstrated in polarized cells by the fact that the sites of fusion at the cell surface are not
randomly distributed but subject to control. Studies of constitutive transport in polarized cells
and in budding yeast have allowed the identification of multiple regulators of this process. Rab8,
Rab13 and Rab11 have been implied in the regulation of the TGN-to-plasma membrane traffic.
They could act on different routes of the constitutive pathway, or act sequentially on the same
one (128). ARF proteins play a role in the budding of constitutive vesicles from the TGN, as
demonstrated by inhibition of their formation by brefeldin A (BFA) (130). Heterotrimeric G-
proteins appear to regulate the formation of both constitutive and regulated secretory vesicles
from the TGN (132). Protein kinase D (PKD) regulates the fission from the TGN of transport
carriers that are directed to the cell surface (133).
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1.4.2 Regulated secretion
Constitutive and regulated exocytosis differ by three main characteristics (126). First, regulated
secretion is coupled to an extracellular stimulus , which leads to a transient rise in intracellular
Ca2+ or another second messenger. Second, in regulated exocytosis the cargoes destined to be
released are accumulated and concentrated within specialised organelles, which are not ubiq-
uitous among cell types; while a constitutive secretory cell shows up to two-fold concentration
of the secretory product from the ER to the secretory vesicle, a cell which secretes in a reg-
ulated fashion shows up to 200-fold concentration of the secretory product. Third, regulated
secretory cells store secretory vesicles within their cytoplasm even for long periods of time.
Regulated secretory cells include neurons, endocrine, neuroendocrine and exocrine cells, mast
cells, platelets, large granular lymphocytes and neutrophils (134).
Two routes of regulated secretion can be distinguished (126; 135). One route releases
molecules synthesized in the ER, modified in the Golgi and packaged in secretory vesicles at
the TGN. The other one releases molecules synthesized in the cytosol and taken up into secre-
tory vesicles. The first pathway is followed by polypeptides (e.g. insulin, glucagon, granins,
parathyroid hormone), while the second is for low molecular weight factors, such as neurotrans-
mitters (e.g. cathecolamines, acetylcolin, glutamate). The difference between the two path-
ways corresponds at the morphological level to two distinct types of organelles. In neurons,
based on early observations at electron microscopy, these are defined as small clear synaptic
vesicles (SVs), ∼50 nm in diameter, for classical neurotransmitters, and large dense core (for
the presence of an electron-opaque content separated or not from the membrane by a clear
space) vesicles (LDCVs) or more generically secretory granules (SGs), ∼200 nm in diameter,
for neuropeptides (136; 137). In endocrine cells the same organelles are called synaptic-like
microvesicles (SLMVs) and LDCVs or SGs, respectively (138). Neurotransmitter and peptide
secretion differ also in terms of exocytosis. Exocytosis is fast (∼200 µsec) and short-lasting for
SVs, with secretion in restricted synaptic active zones. It is slow (from milliseconds to seconds)
and less precisely targeted for LDCVs (135). Concerning the molecular exocytotic machinery,
the majority of the proteins that function in regulated exocytosis has been studied in SVs, at
synapses. Synaptic vesicles are indeed abundant within nerve terminals and relatively easy to
purify. Nevertheless, both SVs and LDCVs share an overall similar molecular composition, not
only at the level of components present in their membrane, but also at the level of cytoplasmic
and plasma membrane components that participate in the exocytosis (134; 139).
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1.4.2.1 Biogenesis of SVs and LDSVs
SVs are known to be docked at specialised area of synaptic plasma membrane, the active sites,
where they undergo fast discharge and rapid recycling. They are thought to originate from con-
stitutive vesicles which undergo exocytosis, through local recycling of the plasma membrane.
The neurotransmitter, synthesized in the cytosol, is taken up into these vesicles, by active
transport through a specific transporter (130; 140). At the active sites, SVs are organized in
two distinct pools in dynamic equilibrium: the readily releasable pool (RRP) and a much larger
reserve pool. This belief has been proposed already 50 years ago (141), and successively gen-
eralized and corroborated (140; 142). The RRP is constituted of vesicles that can be released
in response to a stimulus, without further maturation steps. The reserve pool is reversibly
anchored to the actin cytoskeleton and can be recruited to the RRP upon completion of matu-
ration (142). Electrophysiological measurements suggest that in the various synapses, the size
of the releasable pool varies, thus accounting for different proportions (0.5-10%) of the total
vesicles content. The transit from the reserve to the releasable pool is modulated by the action
of synapsins, which anchor SVs to the actin cytoskeleton. Upon increase in Ca2+ concentration
synapsins are phosphorylated. The phosphorylation of synapsins reduces their affinity to actin
and allows SVs to redistribute to the RRP (143). In addition to synapsins other proteins,
such as the Rab3, have been suggested to regulate SVs movement along the cytoskeleton. The
detailed mechanisms of these events, however, is still unclear (140; 143).
As already mentioned, the biogenesis of secretory granules begins in the TGN, where reg-
ulated secretory proteins (RSP) are sorted, aggregated and packaged into organelles, defined
as immature secretory granules (ISGs), which successively are converted in mature secretory
granules (MSGs or simply SGs) (144; 145) (Fig. 1.13).
The precise mechanism of sorting of RSP from the TGN in ISGs (and their retention in the
ISGs during maturation) is not clearly understood. The research of common sorting signals
in RSP has led to the identification of a conserved N-terminal loop in chromogranins A and
B (CgA and CgB) and in another secretory protein, the pro-opiomelanocortin (POMC) (146),
which seems to play a role in the sorting of these proteins. Other secretory proteins, however,
such as insulin, do not contain this type of loop. A different “sorting domain” seems instead to
be present in the B-chain of the mature insulin (147). Moreover, to date, no “sorting receptor”
in the TGN has been identified.
A model has been proposed for the formation of ISGs, according to which RSP aggregate
in the slightly acidic pH and high Ca2+ concentration present in the TGN environment. This
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leads to the reorganization of cholesterol-rich microdomains in the TGN and to the budding of
ISGs from the TGN (148). Many of the secretory proteins are synthesized as precursors, from
which the active protein is liberated by proteolysis: processing usually begins in the TGN and
is completed in the ISGs. The processing is operated by pro-hormone convertases (e.g. PC1/3,
PC2 and carboxypeptidase E/H (CPE/H)) (149). In the case of insulin, the pro-insulin forms
examers in the TGN, and as such it is exported in the ISGs. Aggregation and crystallization
occurs only upon processing, in the examers, of pro-insulin to insulin (150). Granins, a family
of proteins to which CgA and CgB belong to, seem to play a role as helpers of packaging, sorting
and aggregation (151).
ISGs which bud from the TGN, undergo maturation to become MSGs. During this step
pro-hormones are processed by endopeptidases known as pro-hormone convertases (PC). ISGs
have discontinuous mantle of clathrin, which, however, does not play a role in the budding of
ISGs rather in their maturation (146; 152), for the removal, through clathrin-coated vesicles,
of soluble peptides, unprocessed pro-hormones, missorted proteins and random material that is
not supposed to be in the MSGs. Recently, it has been shown that GGA (described in section
1.3.2 on page 14) is the adaptor protein recruiting clathrin on the ISGs (153). During their
maturation the secretory granules change size upon condensation of the soluble content and the
removal of material via clathrin-coated vesicles. In cells like chromaffin PC12 cells, ISGs may
also undergo homotypic fusion as part of their maturation process (146; 154).
In a few number of cells that undergo to regulated secretion, the pool of SGs is fully re-
leasable upon stimulation: this is the case for mast cell. In most of regulated secretory cells
however, at least two distinct pools of SGs exist (in analogy to the SVs): a readily releasable
pool (RRP), consisted of immobile granules near the plasma membrane, and a reserve pool.
Notably the RRP (1-5% of the total granules) is preferentially composed by newly synthesized
granules (155; 156). Microtubules seem to play a role in this phenomenon: newly synthesized
granules are preferentially released because they preferentially associate with microtubules and
are therefore located closer to the plasma membrane, if compared with “old” granules. As
for the SVs, the recruitment of SGs to the RRP is regulated by their trapping in the actin
cytoskeleton, in particular in the cortical actin meshwork (the so-called “cell web”). Stimu-
lation of secretion and increase in Ca2+ concentration, seems to activate phosphorylation of
specific substrates and to reduce the affinity of SGs to actin, allowing SGs to redistribute to
the RRP and to be secreted. The molecular players of this mechanism seem to be better
understood in insulinoma cells, where SGs are trapped in the actin cortex by the receptor
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A B
Figure 1.13: Biogenesis of secretory granules
A) Immature secretory granules (ISGs) budding from the TGN undergo progressive maturation
in secretory granules (MSG) by homoypic fusion and removal of all the ISGs components which
are not destined to be part of the SG, by clathrin-coated vesicles (CCVs). During the matu-
ration of the ISGs the secretory proteins mature as well, through cleavage by convertases and
aggregation. Modified from (146). B) Electron micrograph showing secretory vesicles forming
from the trans-Golgi network in a insulin-producing β-cell of the pancreas. The black dots are
relative to immuno-gold labeling of clathrin. The ISGS (open arrow), contain clathrin patches,
while the mature SGs (solid arrow) do not show this patches anymore, while showing a highly
condensed core. Reproduced from (58), by courtesy of L. Orci.
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tyrosine phosphatase-like protein ICA512, a transmembrane protein which binds, through β2-
syntrophin and utrophin, the actin cytoskeleton. Upon stimulation of insulin secretion, and
as result of phosphorylation/dephosphorylation of β2-Syntrophin, the interaction between the
latter protein and ICA512 is loosened and SGs can be secreted (157).
1.4.2.2 Exocytosis of SVs and SGs
The stages of regulated exocytosis and the basic fusion machinery involved in this processes
have been shown to be essentially the same for the two types of organelles (SVs and LDCVs)
(126), although the different kinetics suggests that some specific factors are also needed. As
for all the vesicles cycle (described in section 1.3 on page 6), the exocytotic vesicle cycle can be
divided into 5 distinct steps, as schematically illustrated in Fig. 1.14 A: targeting, tethering,
docking, priming and fusion. Targeting is defined as SVs and LDCVs transport to the release
sites. Tethering as the initial, not stable contact between organelles and release sites. Docking is
the attachment to the membranes. Priming is the maturation step through which the organelles
become competent for final release. Finally the fusion leads to the release of the secretory vesicle
content in the extracellular space (134; 139).
The same kind of components already described in section 1.3 on page 6 and seq. (Rab
proteins, SNAREs, NSF and SNAPs) are involved in exocytosis, with one important “new
entry”: the Ca2+-binding proteins. The SNAREs associated with regulated exocytosis are
synaptobrevin (also called vesicle-associated membrane protein or VAMP) on the vesicle, and
syntaxin1 and SNAP-25 on the plasma membrane (139). It is still not clear which factors are
involved in the tethering and docking steps. It is possible that SNAREs are not essential for
this steps, since the number of vesicles docked to the plasma membrane is not decreased in
cells poisoned with clostridial toxins (known to block neurotransmitter release by cleaving the
SNAREs) (158). SNAREs seem instead to be essential for the last steps, the priming and the
fusion (104). Other factors, most probably Rab proteins, might be responsible for the tethering
and docking steps (159). More in detail, Rab3a for SVs and Rab3a and/or Rab27a for SGs
seem to be involved in these processes (139; 160; 161).
Priming events render vesicles competent for fusion with the plasma membrane (primed
vesicles constitute the RRP, which undergo to rapid exocytosis in response to an increase in
Ca2+ concentration). The priming step is ATP-dependent, and involves several processes.
NSF (described earlier in section 1.3.7 on page 20) is necessary to dissociate SNARE complexes
formed within a single membrane in favor of a productive trans-SNARE complex (162). Protein
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A B
Figure 1.14: Exocytosis of secretory vesicles
A) The recruitment of a secretory vesicle to the readily releasable pool (RRP) involves it’s
tethering and docking to the plasma membrane (1), and it’s ATP-dependent priming (2). Fol-
lowing Ca2+ signaling the secretory vesicle fuses to the cell surface and discharge its content.
Ca2+entry leads also to the disassembly of the cortical actin cytoskeleton, which traps the vesi-
cles reducing the mobility of the secretory vesicles close to the plasma membrane. B) Electron
micrograph showing the release of insulin from a pancreatic β-cell. Reproduced from (58), by
courtesy of L. Orci.
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phosphorylation (Calmodulin -dependent kinase, protein kinase A (PKA) and protein kinase C
(PKC)) seem to play a role in priming, as well as phospholipid phosphorylation, and in particular
formation of PI(4,5)P2. PI(4,5)P2, in turn, binds and regulates Ca2+-binding proteins such as
synaptotagmin and CAPS (Ca2+ dependent activator protein for secretion) (163; 164). Another
event during priming is the action of munc13 (a SM protein described earlier in section 1.3.7
on page 20) in removing the inhibitory effect of munc18 (a SM protein) on syntaxin1 (139).
The central role of Ca2+ in regulated exocytosis has been recognized for many years. Most
exocytotic fusions are induced, indeed, by an increase in the intracellular concentration of Ca2+.
SVs require a higher Ca2+ concentration (100-200 µM) than SGs (1-10 µM) (135). In neuro-
transmission the action potential induces the opening of Ca2+-channels and the increase in Ca2+
concentration. Conversly, in secretion of SGs, an extracellular stimulus leads to the opening of
Ca2+-channels. Synaptotagmins represent the best and most characterized Ca2+-sensors (165).
Synaptotagmins are transmembrane proteins that can bind phosholipids through two C2 do-
mains (similar to the lipid-binding domain in PKC), can bind Ca2+, and in a Ca2+-dependent
fashion undergo conformational changes and interact with other proteins involved in regulated
exocytosis (e.g. SNAREs) (166). At least 15 synaptotagmins have been identified, and among
them two seem to have a main role in SVs and SGs exocytosis, synaptotagmin1 and synaptotag-
min3 respectively. Synaptotagmin1, shows low Ca2+ affinity, which is consistent with the high
Ca2+ concentration required for neurotransmitter release (167). Synaptotagmin3, which does
not bind pospholipids through the C2 domains, has a higher affinity for Ca2+ which makes it a
better Ca2+-sensor for secretion of SGs, that requires a much lower Ca2+ concentration (168).
Notably both synaptotagmins can interact with Ca2+-channels. Synaptotagmin1 interacts with
the N-type Ca2+-channel involved in neurosecretion, while synaptotagmin3 interacts with the
L-type Ca2+-channel involved in secretion of SGs (169); the same Ca2+-channels also interact
with syntaxin1 and SNAP-25: this ensures that Ca2+-entry is restricted to the areas where SVs
or SGs are located. CAPS is other putative Ca2+-sensor, specific for SGs. It can bind Ca2+
(at low affinity) and PI(4,5)P2 and it seems to be involved in regulated exocytosis (170).
Mobilization of intracellular Ca2+ stores (meaning from the ER) does not seem to be a
major determinant in regulated secretion.
Upon Ca2+ signaling , and as illustrated in Fig. 1.10 (Ca2+ is the factor that in secretory
vesicles exocytosis determines the “zipping” of the SNAREs), the SVs and SGs fuse to the
cell surface and discharge their content. How the trans-SNARE complex, already but not
tightly assembled in the priming step, causes fusion is still open to questions. In summary,
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the hypotheses may be grouped according to two possible models. In the first proposal, during
the assembly of the “trans complex”, membranes are so close that the hemifusion state favours
their final contact and the formation of a lipidic fusion pore. In the second model, the fusion
pore forms a sort of proteinaceous channel connecting the two opposing membranes (171).
After fusion, and as already described in section 1.3.7 on page 20, NSF and SNAPs cause the
disassembly of the SNARE complex.
After discharge, vesicles are retrieved from membrane surface. SVs are locally recycled and
refilled with neurotransmitter for another exocytotic cycle, while the LDCVs are refilled via
the Golgi-complex. Two models have been proposed since the early ’70s for vesicles recycling
at synapses, schematically illustrated in Fig. 1.15. In the first model, recycling occurs through
endocytosis via clathrin-coated vesicles (172). According to an alternative model, known as “kiss
and run”, recycling occurs through coupled exo-endocytosis (173). The recycling through CCVs
model involves the dispersal of SV components in the plasma membrane following exocytosis,
their reclustering, probably through the adaptor complex AP-2 and the consequent budding of a
CCV (174). In the “kiss and run” model, neurotransmitter is released through a fusion pore that
transiently and reversibly opens during exocytosis. Vesicles are therefore molecularly preserved
and simply need to be refilled by uptake systems present in situ in nerve terminals (173).
The same two models have been proposed for the secretion of SGs (175; 176), with addition
of an intermediate model, known as “semifusion”. This model involves the establishment of
a large opening between the SGs and the extracellular space, even though the SGs remain
structurally intact (177). Experimental data do not favor either model. CCVs are abundant in
nerve terminals and block of clathrin-mediated endocytosis determines paralysis in the mutant
known as shibire in Drosophila. These data would favor the first model (140). On the other hand
the first model can explain with some difficulties continuous secretion for sustained stimulation.
This consideration, together with capacitance measurements and amperometric assays, favors
the “kiss and run” model (178). Recent investigations strongly suggest that both pathways,
coated pits and kiss-and-run, are employed in parallel, although at different rates. Both routes
coexist in the same terminal, and that the contribution of kiss-and-run increases (up to 80%)
at high frequencies of stimulation (179).
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Figure 1.15: Secretory vesicle recycling
Two pathways are proposed to explain synaptic vesicle recycling. The first pathway (up)
implicates conventional exocytosis, with intermixing of the vesicle and plasma membrane com-
ponents. Follow clathrin-mediated retrieval of the vesicle components, their delivery to the
endosome and the budding of synaptic vesicle from the endosome. In the kiss-and-run model
(bottom) the fusion pore is closed shortly after its opening. According to this model, the vesi-
cle maintains its identity and simply needs to be refilled with neurotransmitter. The same two
models have been proposed in the secretion of SGs. Reproduced from (140).
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1.4.3 Insulin-containing SGs
Insulin1, the most important hormone for glucose homeostasis, is produced in the β-cells of
the pancreatic islets of Langerhans (180). Discovered in 1869 by Paul Langerhans, the islets
of Langerhans constitute approximately 1 to 2% of the mass of the pancreas. Each pancre-
atic islet contains few thousands cells and is 50-500 µm in diameter. Hormones produced
in the islets of Langerhans are secreted directly into the blood flow by (at least) four dif-
ferent types of cells (neuroendocrine cells) (181): insulin producing β-cells (70-80% of the
islets cells), glucacon-releasing α-cells (15-20%), somatostatin-producing δ-cells (5%), pancre-
atic polypeptide-producing PP cells also called γ-cells (up to 1%).
Insulin is the primary anabolic hormone, promoting glucose uptake into the cells, glycogen
and triglyceride synthesis and inhibiting hepatic gluconeogenesis. Additionally, insulin regulates
other cellular events such as protein and DNA synthesis and amino acid (aa) transport (182).
Insulin is produced only in β-cells (Fig. 1.16), and the regulation of its expression depends on
an elaborate set of transcription factors which tightly regulate insulin gene expression also in
response to physiologic signals such as glucose (183). Another important step in the regulation of
insulin expression is the post-transcriptional regulation of its mRNA. Stimulation of the β-cells
with high glucose leads to an increase in insulin biosynthesis up to 20-fold. Several mechanisms
are involved in the increased translation: increase of the initiation of translation and increase
in the elongation rate of the nascent peptide, increased binding to the SRP and translocation
in ER (184). Recently it has been shown that glucose increases also insulin mRNA stability,
through the binding of polypirimidine tract-binding protein (PTB) to its 3’-untranslated region
(3’ UTR). This mechanism stabilizes also other mRNAs encoding proteins of the SGs (185).
Insulin secretion occurs upon increase of glucose concentration in the blood, (in healthy
individuals plasma glucose is on a range between 3.9 and 6.1 nmM (70 and 110 mg/dL)).
Glucose is the primary signal that triggers SGs exocytosis. Other signals, however, like amino
acids or long-chain acyl-CoA, derived from glucose and from free fatty acid (FFA), play a
role in insulin secretion (186). β-cells store insulin in SGs (described earlier in this section).
Ultrastructural studies have shown that a single β-cell contains ∼13000 granules (187), of which,
as described earlier, ∼5% belongs to the RRP.
1Insulin is the first hormone which has been discovered, in 1922 by the collaboration of Frederick Banting
and Charles Best with J.J.R. Macleod and James Collip; in 1923 Banting and Macleod were awarded the Nobel
Prize in Physiology of Medicine for the discovery of insulin.
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Figure 1.16: Pancreatic β-cell
Electron micrograph of a high pressure frozen islet cell (by Joke Ouwendijk).
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Glucose enters the β-cell through the low-affinity glucose transporter-type 2 (GLUT-2), and
after phosphorylation by glucokinase (GK), it goes into the glycolysis and the respiratory cycle,
with consequent ATP production and increase in the ATP/ADP ratio. This controls the clo-
sure of ATP-sensitive potassium (K+ATP ) channels on the plasma membrane. The consequent
depolarization of the membrane causes the opening of voltage gated L-type Ca2+-channels. The
local increase in Ca2+ concentration, in turn, determines exocytosis of SGs (188). Actually,
and because of the allosteric regulation of the glycolytic enzyme phosphofruttokinase (PFK),
glucose determines oscillations in the ATP/ADP ratio, with consequent oscillations in mem-
brane potential and oscillations in the local Ca2+ concentration. This phenomenon gives rise
to pulsatile insulin secretion (189; 190). Furthermore patch-clamp and amperometric measure-
ment have established that insulin secretion in response to glucose stimulation is biphasic1 and
consists of a rapid release phase and a slower, sustained phase, during which secretion continues
at a lower rate in compared to the first phase (192; 193). The first phase of insulin secretion
corresponds to the exocytosis of the RRP, already primed and therefore competent for secretion.
The second phase correspond to the exocytosis of the reserve pool. This phase is slower than
the first one, reflecting the time SGs need to be recruited, docked and primed at the plasma
membrane (164; 169; 194). The molecular machinery involved in insulin secretion has already
been described earlier in this section.
β-cells are able to couple the consumption and the production of SGs. Upon stimulation
several processes are activated in order to renew granule stores. Recently, a putative mechanism
which couples this two processes has been identified in insulinoma cells. The receptor tyrosine
phosphatase-like protein ICA512, a transmembrane protein of the SGs, is indeed cleaved after
exocytosis of SGs, and the cytosolic fragment generated translocates to the nucleus, binds the
transcription factor STAT5 and promotes insulin gene expression. This allows the β-cell to
monitorate the consumption of SGs (195; 196).
1.5 Diabetes
Diabetes mellitus (or simply diabetes) is a complex metabolic disorder characterized by hy-
perglycemia, disturbance of carbohydrate, fat and protein metabolism resulting from defects in
insulin secretion, insulin action or both. Diabetes comprehends type 1 diabetes, type 2 diabetes,
maturity-onset diabetes of the young and gestational diabetes (197).
1Mice deviate from this behavior, showing a first and transient phase in insulin secretion, followed by a very
weak second phase (191).
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1.5.1 Type 1 diabetes
Type 1 diabetes (T1D) (also known as insulin-dependent diabetes mellitus (IDDM), as im-
mune mediated diabetes (IDM), or as “juvenile diabetes” because it mostly affects individuals
already during their childhood-adolescence) accounts for approximately 5-10% of all diabetes
cases. T1D results from the autoimmune destruction (by CD4+ and CD8+ T-cells and by
macrophages) of the pancreatic β-cells, therefore resulting in insulin deficiency (198). Suscepti-
bility to T1D, indicating the genetic predisposition to T1D, seems to plays a role in the future
development of T1D. In the last years a number of loci have been identified as susceptibility loci
for T1D and between them the HLA DR/DQ region (199). Another important factor which
may lead to T1D is the exposure to environmental factors such as viruses (e.g. enteroviruses,
rotavirus and especially rubella) (200), toxins (e.g. nitrosamines) or food (e.g. cereals, gluten
and cow’s milk proteins) (201).
In T1D the abnormal activation of T-cells leads to insulitis (inflammation of the islets)
with consequent and progressive destruction of the β-cells and to the activation of B-cells with
production of autoantibodies to β-cell antigens. T1D autoantibodies, pointed out in Fig. 1.17,
include antibodies against insulin, CPE/H, islet cell autoantigen 512 (ICA512) and the related
phogrin, islet cell autoantigen 69 (ICA69) and glutamic acid decarboxylase 65/67 (GAD 65/67)
(202). Autoantibodies appear already in the pre-diabetic phase of the disease, allowing therefore
(especially if two or more different autoantibodies are present) the identification of subjects with
high risk of developing T1D (203). Nevertheless there is no evidence that any of this antibodies
has an active role in the pathogenesis of this disease. Recent studies indicate, on the other hand,
that B-cells play an important role in the development of T1D, not as antibody-producing cells,
but as antigen-presenting cells, contributing therefore to the expansion of CD4+ and CD8+
T-cells (204).
1.5.1.1 Autoantibodies in T1D
As pointed out earlier, T1D is characterized by the appearance of a specific set of autoanti-
bodies. Many systemic and organ-specific autoimmune diseases are characterized by high-titer
autoantibodies against intracellular antigens. A frequent finding is that autoimmune targets
of any given disorder are part of the same macromolecular complex. Proteins associated with
nucleic acids are, for example, typical autoantigens in systemic lupus erythematosus (205). Cen-
trosomal proteins are associated with rheumatoid arthritis (206). Golgi or nuclear proteins are
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Figure 1.17: Autoantigens in T1D
Schematic drawing of a β-cell showing the intracellular distribution of known T1D autoantigens.
With the exception of ICA69, all other autoantigens are associated with secretory vesicles.
ICA69 seems to be associated with earlier stages of the secretory pathway.
Increasing evidence suggest that autoimmunity in T1D follows a similar pattern. In the case
of T1D, humoral autoimmunity seems to preferentially target β-cell proteins that are enriched
in Golgi and post-Golgi secretory vesicles, including insulin secretory granules and synaptic-like
microvesicles (202) (Fig. 1.17). These findings have been explained by proposing that in the
course of the disease humoral autoimmunity spreads from one epitope in a single antigen to




1.5.2 Type 2 diabetes
Type 2 diabetes (T2D) is the most common form of diabetes, accounting for approximately
90% of all diabetes cases. T2D is characterized by disorders in insulin secretion and insulin
action1. In most patients, T2D results from alterations in various genes, each having a par-
tial and additive effect. T2D is indeed a polygenic disease (210). During the last years an
increasing number of genes involved in T2D have been identified, some of which are involved in
insulin secretion (e.g. GLUT-2, GK, insulin, K+ATP channels), some others in insulin action
(e.g. insulin receptor, insulin receptor substrate 1 (IRS1), phosphoinositide 3-kinase (PI3K),
hepatocyte nuclear factor 1-α (HNF1α), calpain 10) (211). Another important trigger for the
development of T2D is given by environmental factors (including obesity, lack of physical activ-
ity, smoke or alcohol intake). As pointed out earlier, insulin resistance, meaning the inability
of insulin target tissues to correctly uptake and utilize insulin and the following resistance to
the metabolic effects of insulin, is one of the defects in T2D. For the clinical manifestation of
T2D, however, insulin resistance must be accompanied by a compromised β-cell compensatory
ability (212).
1.5.3 Maturity-onset diabetes of the young
Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes, caused by
specific mutations in one of the MODY-related genes, causing a β-cell dysfunction: MODY-
related genes include GK and β-cell-specific transcription factors (e.g. HNF1α and HNF4α)
(213).
1.5.4 Gestational diabetes
Gestational diabetes is carbohydrate intolerance associated with hyperglycemia with onset or
first recognition during pregnancy. This form of diabetes can have deleterious consequences for
both the fetus and the mother (214). The pathogenesis of gestational diabetes resembles that
of T2D and it seems to be caused by some of the hormones produced in the placenta, which
can have a blocking effect on insulin (the so-called “contra-insulin” effect).
1Insulin initiates its effect on target tissues by binding a specific membrane receptor on their plasma mem-
brane, the insulin receptor (IR), thus activating its tyrosine-kinase activity which leads to the phosphorilation
of endogenous substrates and in particular IRS-1 (insulin receptor substrate 1). IRS-1, in turn, activate several
cytosolic signaling components, including phosphatidilinositol 3-kinase (PI3K) and p21ras (182).
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1.6 Islet Cell Autoantigen 69
Islet Cell Autoantigen of 69 kDa (ICA69) was originally identified by screening an islet cDNA
expression library with sera of pre-diabetic relatives of patients with T1D (215). ICA69 was
shown to migrate as a 69 kDa protein by SDS-PAGE. The corresponding gene, designated as
ICA1 in humans and Ica-1 in mice, was mapped on chromosome 7 and 6 in the two species. The
rat ICA69 was cloned afterwards, and the correspondent gene was mapped on chromosome 4
(216). Alternatively spliced variants which encode different protein isoforms have been described
in different species. However, not all variants have been fully characterized (being the 69 kDa
isoform the most studied) (217). As most autoantigens of T1D, ICA69 is primarily expressed
in neuroendocrine tissues, with peak levels in brain and in pancreatic islets (215; 218). Recent
studies have shown that the tissue expression of this protein is affected by three distinct 5’-
untraslated (5’ UTR) exons representing three different promoters (exons A, B or C). More in
detail, exon A transcript predominate in islet cells, exon B transcripts in neuronal cells (219).
Despite not being a main autoantigen of T1D (whose antibodies are the first to appear in
the development of T1D, like insulin, ICA512 and GAD 65 (220)) and not being an obligate
autoantigen of T1D, still ICA69 is a target autoantigen1 in T1D (215). Moreover, nonobese
diabetic (NOD) mice (the experimental model for the study of autoimmune diabetes) show a
loss of self-tolerance to ICA69 (222). ICA69 is an antigen also in autoimmuno diseases other
then diabetes. ICA69 autoantibodies have been shown, indeed, in rheumatoid arthritis and in
primary Sjo¨gren’s syndrome (223; 224).
ICA69 is partially cytosolic and soluble, although a subfraction appears to be membrane-
bound, as shown by subcellular fractionation studies in murin brain tissues and insulinoma
cells. More in detail, it appears to be associated, at least partially, with the Golgi complex
(225; 226).
ICA69 function is still unknown, but a mutation of its homologue ric-19 in Caenorhabditis
elegans confers resistance to the drug aldicarb, an inhibitor of acetylcolinesterase, consistent
with a defective neurotransmitter secretion in the mutant and an involvement of ICA69 in neu-
rosecretion (225; 227). Nevertheless ICA69null NOD mice have no obvious phenotype and age
normally. ICA69null NOD females develop diabetes at essentially wild-type NOD incidence,
1The antigenic determinant in ICA69 is called Tep69 T-cell epitope, encompassing amino acids 36-47 of
human ICA69 (221).
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by they are highly resistant to cyclophosfamide-induced diabetes progression. How cyclophos-
famide accelerates islets destruction is not well understood, but it may require the ICA69
protein (228).
Recently, sequence and structural analyses, have revealed the presence of a BAR domain in
the N-terminal region of ICA69 (113; 226). The BAR domain proteins, as described in section
1.3.8 on page 23, are mostly involved in intracellular transport. This finding has provided new
motivation in the investigation of the still unknown cellular function of ICA69, and its putative
role in intracellular membrane trafficking.
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Chapter 2
Aim of the thesis
The main aim of this thesis was to study the role of ICA69 in context of membrane trafficking.
Several lines of evidence point to an involvement of this protein in membrane traffic:
• ICA69 was historically identified as a T1D autoantigen. As described in section 1.5.1.1
on page 40, in T1D autoantibodies are preferentially directed against β-cell proteins that
are enriched in Golgi and post-Golgi secretory vesicles.
• Even though ICA69 function is still unclear, a mutation of ICA69 homologue in C. elegans
impairs acetylcholin release at the neuromuscular junctions, thereby suggesting an involve-
ment of ICA69 in regulated secretion.
• Preliminary evidence indicate that ICA69 is associated with the Golgi complex, in agree-
ment with its putative involvement in neurosecretion.
• ICA69 contains, in the N-terminal region, a BAR domain. The BAR domain, described in
section 1.3.8 on page 23, is present in several proteins involved in intracellular transport
and functions as dimerization motif, provides a general binding interface for different
types of GTPases and it is a membrane binding/bending module.
In the course of this thesis it was therefore investigated whether ICA69, similar to other proteins
containing a BAR domain, plays a role in intracellular membrane traffic and in particular in
the trafficking of proteins targeted to the insulin secretory granules.
Part of the thesis was also devoted to the study of an ICA69 paralogue gene, called ICA69-
RP. This is a novel gene whose expression, like that of many components of the regulated
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secretory machinery in β-cells, is glucose regulated, therefore pointing to the involvement of
this protein in insulin secretion.
In brief, the study of β-cell autoantigens with yet unknown function may provide insight
into the secretory machinery of β-cell, and lead to the discovery of novel pathways. Further-
more, the characterization of proteins containing a BAR domain, here the two members of the
ICA69 protein family, with emphasis on their interaction with small GTPases, could elucidate





3.1 ICA69 cellular localization
ICA691 cellular localization was investigated in the rat insulinoma cell line INS-1, as ICA69
was shown to be highly expressed in islet-derived cell lines (215).
Confocal microscopy shows a cytosolic distribution of ICA69, the punctate “vesicular” stain-
ing consistent with the interaction of a pool of the protein with membranes (225; 226). ICA69 is
enriched in the perinuclear region2, where also markers of the Golgi region are found (Figs. 3.1
and 3.2). More in detail ICA69 partially co-localizes with GM130, marker of the cis-medial
Golgi compartment, and with TGN38, marker of the TGN, even though ICA69 shows a broader
distribution than these Golgi markers. No significant co-localization is found between ICA69
and concavalin A, a lectin which specifically binds α-mannopyranosyl α-glucopyranosyl sugar
residues, or the membrane-anchoring tail of the citocrome b in fusion with GFP (called btail-
GFP), both markers of the ER, or β-COP, component of the coatomer and peripherally asso-
ciated with the Golgi complex.
These results partially confirm previous data (226).
1Two previously characterized α-ICA69 antibodies were used in the experiments reported in this thesis:
a polyclonal antibody raised against residues 471-483 of human ICA69, and a monoclonal antibody, which
recognizes an epitope in the first 230 amino acids of human ICA69 (215; 226). Despite the strong homology at
the protein level between ICA69 and ICA69-RP (see Chapter 4), these α-ICA69 antibodies did not crossreact
with ICA69-RP ( AppendixB, Fig B.1, on page 112). Another antibody was produced in the course of this
thesis, raised against the central region of ICA69. This antibody turned out, however, not to be specific for
ICA69, and was therefore not used in any of the reported experiments.
2The more specific and confined distribution later obtained for ICA69 by immunocytochemistry (compare
Figs. 3.1 and 3.2), was due to the use of a new batch of the antibody, in conjunction with a partially modified
protocol for the immunocytochemistry, which allowed a clearer visualization of the distribution of ICA69.
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Figure 3.1: ICA69 cellular localization.1
Confocal microscopy images from double stained INS-1 cells. A-C: ICA69 (pseudogreen) and
GM130 (pseudored). D-F: ICA69 (pseudogreen) and TGN38 (pseudored). G-I: ICA69 (pseu-
dogreen) and concavalin A (pseudored). Merge in C, F, I. Scale bar: 5 µm.
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Figure 3.2: ICA69 cellular localization.2
Confocal microscopy images from double stained INS-1 cells. A-C: ICA69 (pseudored) and
GM130 (pseudogreen). D-F: ICA69 (pseudogreen) and btail-GFP (pseudogreen). G-I: ICA69
(pseudogreen) and β-COP (pseudogreen). Merge in C, F, I. Scale bar: 5 µm.
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3.2 Binding of ICA69 to lipids
As described in section 1.3.8 on page 23, relative to proteins with a BAR domain, the BAR
domain is a membrane binding/bending module. Therefore ICA69, with a BAR domain at
its N-terminus, was likely to bind lipids. In order to elucidate the lipid binding properties of
ICA69, a protein-lipid overlay assay was performed. Nitrocellulose filters spotted with various
phospholipids (PIP Strips) were incubated with purified ICA69-GST in an overlay assay, and
binding of ICA69 to specific phospholipids was detected by blotting with an α-GST antibody.
GST was used as negative control. Amphiphysin1-GST, known to bind membrane lipids, was
instead used as positive control.
The results of the experiment are reported in Fig. 3.3. ICA69 interacts with several mem-
brane lipids, including PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3.
Furthermore, densitometry performed on the PIP strip shown in Fig. 3.3, indicate that the lipid
which ICA69 binds the most is PI(4)P, enriched in the Golgi region.
3.3 Binding of ICA69 to Rab2
Previous studies pointed to the interaction of ICA69 with a small GTPase (226) whose identity,
however, remained to be established. In the meantime Francis Barr (MPI for Biochemistry,
Martinsried, personal communication) found that ICA69 interacts with Rab2 by two-hybrid
system in yeast. As Rab2 is involved in the trafficking between the ER and the Golgi complex
(30; 63; 229), and ICA69 is associated with the Golgi complex, this interaction was likely to be
relevant and therefore further analyzed using in vivo and in vitro approaches.
3.3.1 Interaction ICA69/Rab2 by immunoprecipitation assays
The putative interaction between ICA69 and Rab2 was first analyzed by immunoprecipitation
experiments. For this purpose INS-1 cells were transfected with a plasmid expressing Rab2
in fusion with GFP or with a plasmid expressing GFP as negative control. The Triton X-100
soluble fraction of transfected cells was then incubated with an α-GFP antibody and then with
Protein G resin in order to bind GFP, or Rab2-GFP and isolate in this way presumed complexes
containing Rab2-GFP and ICA69. Incubation mixtures were washed and then resolved by
SDS/PAGE, followed by western blotting. The results of the experiment are reported in Fig. 3.4.
ICA69 co-immunoprecipitated with Rab2-GFP (lane 5, from cells transfected with pEGFP-
Rab2) but not with GFP (lane 6, from cells transfected with pEGFP-N1).
49
3.3 Binding of ICA69 to Rab2
Figure 3.3: ICA69 binds to membrane phospholipids
GST, ICA69-GST or amphiphysin1-GST were used in a protein-lipid overlay assay employing
PIP strips. The lipids spotted at each position in the PIP strips are indicated at the bottom.
The experiment was repeated twice, with similar results.
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Figure 3.4: Interaction between ICA69 and Rab2 in vivo
INS-1 cells were transfected with pEGFP-Rab2 or with PEGFP-N1, and immunoprecipitations
(IP) were carried out using an α-GFP antibody. The antibodies used for the western blotting
are indicated at the bottom. Lanes 1 and 2: Rab2-GFP and ICA69 in the input. Lane 3:
IP for Rab2-GFP. Lane 4: IP for GFP. Lane 5: co-IP of ICA69 from cells transfected with
pEGFP-Rab2. Lane6: absence of co-IP of ICA69 from cells transfected with pEGFP-N1.
3.3.2 Interaction ICA69/Rab2 in pull down assays
The potential in vivo interaction was further evaluated with GST pull down assays. Rab2-
GST loaded with GDP or with GTPγS, and previously immobilized on beads, were incubated
with INS-1 Triton X-100 soluble fraction. Incubation mixtures were washed and then resolved
by SDS/PAGE, followed by western blotting. The results of the experiment are reported in
Fig. 3.5. Rab2 pulls down ICA69 from the cell extracts, only in its GTP-bound state (lane 4),
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but not in its GDP-bound state (lane 3). As an additional negative control, GST alone cannot
pull down ICA69 (lane 2). As positive control in this assay, the interaction between Rab2
and GM130 was investigated, as GM130 is reported to be a Rab2 effector (230). Surprisingly
GM130 did not appear to interact with Rab2 (data not shown).
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Figure 3.5: Interaction between ICA69 and Rab2 in vitro
GST pull down assay: GST (lane 2), Rab2-GST loaded with GDP (lane 3) and Rab2-GST
loaded with GTPγS (lane 4) were immobilized on beads and incubated with INS-1 cells Triton
X-100 soluble fraction. Bound proteins were eluted and fractionated by SDS/PAGE, followed
by western blotting with an α-ICA69 antibody. The input (10%) is shown in lane 1.
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3.3.2.1 Specificity of the ICA69/Rab2 interaction
To investigate the specificity of the interaction between ICA69 and Rab2, pull down assays were
performed also with different Rab proteins, verifying their functionality through the binding
of the latter to known effectors (Fig. 3.6). The choose of the specific Rab proteins to use for
this assay was dictated by their location within the cell, namely Rab proteins which shared
similar, though not identical, location and/or function with Rab2, as for Rab1, involved in
the anterograde membrane trafficking between the ER and the Golgi complex (61), and Rab6,
Golgi-associated and regulating the trafficking between early and late Golgi compartments and
a Golgi-to-ER retrograde pathway COPI independent (231) or Rab proteins with a different
location and function if compared with Rab2, as for Rab5, required for endosome fusion, and
Rab4, with a role in sorting/recycling in early endosomes (88).
The interaction of ICA69 with Rab2 is specific. ICA69, indeed, is not pulled down by Rab1,
Rab4, Rab5 or Rab6 (loaded with GDP or GTPγS) (Fig. 3.6, upper panels), being these Rab
properly folded and functional as demonstrated by their ability to pull down in their GTP-bound
form, GM130, Rabaptin and EEA1, respectively (Fig. 3.6, lower panels). Only in the case of
Rab6, it was not possible to demonstrate in the same way its functionality because of the lack
of an antibody against a known effector of this protein, to be used in the western blotting. The
purification of this Rab protein and its loading with the nucleotide was nevertheless performed
in parallel with the purification and the loading of the Rab2 protein used for the pull down
showed in Fig. 3.6.
Interestingly, in the conditions used for the pull down experiments, the known effectors of the
Rab used as controls clearly interact in a GTP-dependent fashion, but their interaction appears
to be quite weaker than the association of Rab2 with ICA69 (compare input and GTPγS in
each panel).
3.3.3 Interaction ICA69/Rab2 by immunocytochemistry
ICA69 was found to be enriched in the perinuclear region (Figs. 3.1 and 3.2), while Rab2
is a resident protein of the intermediate compartment (together with ERGIC53), located in
proximity of the Golgi complex, in the perinuclear region (232). The interaction between
ICA69 and Rab2 was further investigated by immunocytochemistry, to better explore where,
within the cell, it occurred.
Confocal microscopy on INS-1 cells transfected with a plasmid encoding Rab2 in fusion
with GFP, shows that ICA69 and Rab2-GFP mostly colocalize in particules throughout the
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Input= 1/10 starting material
ø = pull down with GST
GDP = pull down with Rabn loaded with GDP
GTPγS = pull down with Rab loaded with GTPγS  
 WB:αRabaptin 
WB: αICA69                   
Figure 3.6: Specificity of the ICA69/Rab2 interaction
GST pull down assays with Rab2-GST, Rab1-GST, Rab4-GST, Rab5-GST, Rab6-GST. For
each panel, but the last bottom panel on the right: GST (lane 2), Rab-GST loaded with GDP
(lane 3) and Rab-GST loaded with GTPγS (lane 4) were immobilized on beads and incubated
with INS-1 cells Triton X-100 soluble fraction; last bottom panel on the right: Rab-GST loaded
with GDP (lane 2) and Rab-GST loaded with GTPγS (lane 3) were immobilized on beads
and incubated with INS-1 cells Triton X-100 soluble fraction. Bound proteins were eluted
and fractionated by SDS/PAGE. The input (10%) is shown in lane 1. Western blotting was
performed using an α-ICA69 antibody (upper panels), or an α-GM130 (for Rab1), α-Rabaptin
(for Rab4) or α- EEA1 (for Rab5) antibodies.
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Figure 3.7: ICA69 cellular localization in Rab2-GFP expressing-INS-1
Confocal microscopy images from INS-1 cells transfected with pEGFP-Rab2. A, D, G: im-
munolabeling for ICA69 (pseudored). J: negative control (secondary antibody only). B, E, H,
K: GFP fluorescence (pseudogreen). C, F, I, L: merge. Scale bar: 5 µm.
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cytoplasm (Fig. 3.7 A-I, transfected cells). Although the identity of these particulates is not
entirely clear, being Rab2-GFP over-expressed, they are positive for both ICA69 and Rab2.
Interestingly, in cells expressing the highest levels of Rab2-GFP, ICA69 is especially enriched
in a perinuclear structure, where also Rab2 is found (Fig. 3.7 A and G, Fig. 3.13 B-A and
Fig. 3.14 G, arrowheads)1. ICA69 appears to be concentrated in this compartment only upon
over-expression of Rab2-GFP, suggesting a “redistribution”2 of ICA69 within the cell in a
Rab2-GFP dependent fashion. This data is an additional indication that ICA69 binds Rab2.
In order to better define the compartment where ICA69 and Rab2 interacted, additional
immunolabeling assays were performed (Fig. 3.8). Surprisingly, despite both Rab2 and ER-
GIC53 are resident proteins of the intermediate compartment, the signals, obtained by confocal
microscopy, for ERGIC53 and Rab2-GFP in INS-1 cells did nor overlap (Fig. 3.8 G-I), as well as
the signals for β-COP (component of the coatomer and recruited by Rab2 on the intermediate
compartment (63)) and Rab2-GFP (Fig. 3.8 D-F). Consistent with the substantial colocaliza-
tion of ICA69 with Rab2-GFP, also the signals for ICA69 and β-COP did not overlap (Fig. 3.8
A-C).
3.4 Rab2-dependent ICA69 membrane recruitment
The potential Rab2-dependent “redistribution” of ICA69 within the cell was further investigated
by subcellular fractionation. High speed supernatants (HSS, containing cytosolic material)
and high speed pellets (HSP, enriched in detergent-soluble particulate material) were prepared
from INS-1 cells not transfected or transfected with a plasmid encoding Rab2-GFP and then
subjected to SDS/PAGE, followed by western blotting.
The results of the fractionation experiments are showed in Fig. 3.9. In not transfected cells,
and in agreement with previous studies (226), ICA69 is mainly cytosolic, but a pool of the
protein is membrane-associated (Fig. 3.9 A, lane 1 of the first panel from the top and lane 3 of
the second panel). Notably, in cells expressing Rab2-GFP, the signal for ICA69 is decreased in
the HSS (Fig. 3.9 A, compare lanes 1 and 2 of the first panel from the top) and concomitantly
the signal for this protein is increased in the HSP (Fig. 3.9 A, compare lanes 3 and 4 of the
second panel from the top). Fig. 3.9 B shows the quantification of this experiment. Upon
1Clearly this was not due to an artifact caused by a bleed-through of the Rab2-GFP signal in the red channel,
since this structure was not detectable when ICA69 was not immunolabeled (Fig. 3.7 J-L).
2The unchanged ICA69 protein levels in control cells and in cells over-expressing Rab2-GFP (data not
shown) indicated that the increased signal for ICA69 in these latter was due to “redistribution” within the cell
rather than to increased amount of this protein.
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Figure 3.8: ICA69 and Rab2-GFP cellular localization compared with markers of
the intermediate compartment
Confocal microscopy images from INS-1 cells (A-C) or INS-1 cells transfected with pEGFP-
Rab2. (D-I). A, D, G: immunolabeling for ICA69, β-COP and ERGIC53, respectively (pseu-
dored). B: immunolabeling for β-COP (pseudogreen). E, H: GFP fluorescence (pseudogreen).
C, F, I: merge. Scale bar: 5 µm.
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Figure 3.9: Rab2-dependent ICA69 membrane recruitment
A) Subcellular fractionation was performed on INS-1 or INS-1 transfected with pEGFP-Rab2,
as described in Materials and Methods. Followed SDS/PAGE and western blotting with the
antibodies indicated. 20 and 18.5 µg of total protein were loaded on the gel for HSS and HSP,
respectively. The first two panels from the top show the same gel exposed for either for a short
(3 min) or long (11 min) period of time for the acquisition of the signal, as ICA69 is much more
aboundant in the HSS than in the HSP. B) Quantification of three independent experiments,
as in A. Amounts were normalized against γ-tubulin, and not transfected cells were equaled to
100%. The error bar indicates the standard deviation (SD) for the not transfected cells, and
the standard error of the mean (SE) for transfected cells.
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over-expression of Rab2, the signal for ICA69 decreases of 16% in the HSS, and increases of
17% in the HSP. The results are even more significative when the low efficiency of transfection
(∼ 25%) is taken in account.
Therefore, subcellular fraction studies indicate that over-expression of Rab2-GFP correlates
with an increased recruitment of ICA69 to membranes.
3.5 Mapping, in ICA69, of the domain of interaction with
Rab2
Preliminary evidence indicated that the interaction ICA69/Rab2 occurs through the C-terminal
region of ICA69 (F. Barr, personal communication), and not through the BAR domain. This
was unexpected considering that ICA69 contains a BAR domain and that BAR domains act
as binding interfaces for many GTPases (as described in section 1.3.8 on page 23). To verify
whether the C-terminus of ICA69 binds Rab2, a deletion mutant of ICA69, which only con-
tains the C-terminal 230 aa of ICA69 was generated (Fig. 3.10) and expressed in INS-1 cells
(Fig. 3.11).
The truncated mutant of ICA69 was detected in the Triton X-100 soluble fraction of INS-1
cells as a doublet of ∼34 kDa, despite it has a molecular mass of 23 kDa (Fig. 3.11). The
same phenomenon is observed for ICA69, which has a molecular mass of 54 kDa, but an
electrophoretic mobility of 60 kDa. Interestingly, also the C-terminal region of ICA69 appears
as a doublet on protein gels. The origin of the doublet is still unknown. However, its appearance
upon expression of the C-terminal domain of the protein only, suggests it may be due to post-
translational modification of ICA69, rather than alternative splicing or alternative initiation of
the translation in ICA69 mRNA.
This mutant was thereafter used in GST pull down assays, to locate the region of ICA69
which binds to Rab2. As previously described, GST pull down experiments were performed
using Triton X-100 soluble fraction from untransfected INS-1 or from INS-1 expressing the C-
terminus of ICA69 (ICA69woBAR, so called because it encompasses the entire protein excluding
the N-terminal BAR domain), using Rab2-GST loaded with GDP or with GTPγS. The results
of these experiments are reported in Fig. 3.12. Despite Rab2 was functional and properly folded,
as demonstrated by its GTP-dependent interaction with endogenous ICA69 (Fig. 3.12, lanes 3
and 6), it does not interact with the C-terminus of ICA69 (Fig. 3.12, lane 6).
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Figure 3.10: Scheme of ICA69 deletion mutants
The cartoon is relative to ICA69 and two generated deletion mutants, called BAR69, comprising
the N-terminus of ICA69, with the entire BAR domain, and ICA69woBAR, comprising the C-
terminus of ICA69. The cyan indicates high homology regions with ICA69-RP. The red indicates










Figure 3.11: Expression of ICA69 C-terminus in INS-1
Western blotting on Triton X-100 soluble fraction of INS-1 cells (lane 1) or INS-1 transfected
with a plasmid encoding the C-terminus of ICA69 (lane 2), with the polyclonal α-ICA69.
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3.6 Related behavior of ICA69 and Rab2 upon perturbation of early secretory
compartments
Studies are ongoing to test whether the interaction ICA69/Rab2 occurs through the BAR
domain of ICA69. However, all attempts to express the N-terminal half of ICA69 (called











Figure 3.12: Mapping of the domain of interaction with Rab2
GST pull down assay: Rab2-GST loaded with GDP (lanes 2 and 5) and Rab2-GST loaded
with GTPγS (lanes 3 and 6) were immobilized on beads and incubated with Triton X-100
soluble fraction from INS-1 cells (lanes 2 and 3) or INS-1 cells expressing the C-terminus of
ICA69 (lanes 5 and 6). Bound proteins were eluted and fractionated by SDS/PAGE, followed
by western blotting with an α-ICA69 antibody. The inputs (10%) are shown in lanes 1 and 4.
3.6 Related behavior of ICA69 and Rab2 upon perturba-
tion of early secretory compartments
The distribution of ICA69 and Rab2-GFP was further investigated upon incubation of INS-1
cells at 15 ◦C for 80 minutes. Cells were incubated at this reduced temperature to accumulate
and enhance visualization of the intermediate compartment by blocking the anterograde ER-
to-Golgi transport: at 15 ◦C, secretory cargo leaves the ER, but instead of being transported
to the Golgi apparatus, it accumulates in the intermediate compartment (233).
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Figure 3.13: ICA69 distribution upon incubation of INS-1 cells at 15 ◦C
A) Confocal microscopy images from INS-1 cells, kept at 37 ◦C, or incubated at 15 ◦C, and
immunolabeled for ICA69 (pseudored). Scale bar: 5 µm. B) Confocal microscopy images from
INS-1 cells transfected with pEGFP-Rab2, kept at 37 ◦C (A-C), or incubated at 15 ◦C (D-F).
A and D: immunolabeling for ICA69 (pseudored). B and E: GFP fluorescence (pseudogreen).
C and F: merge. Scale bar: 5 µm.
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Immunocytochemistry was performed on control INS1 and INS-1 cells over-expressing Rab2-
GFP, upon incubation at the reduced temperature, and the results are shown in Fig. 3.13. In
control cells ICA69 has a perinuclear distribution (Fig. 3.13 A, 37 ◦C and Fig. 3.13 B (A and C))
with an enrichment in a perinuclear structure were also Rab2 is found in cells over-expressing
Rab2-GFP (Fig. 3.13 B (A-C)). Upon incubation of the cells at 15 ◦C, both in control INS-1 and
in INS-1 over-expressing Rab2-GFP, ICA69 accumulates to a perinuclear structure resembling
that observed upon over-expression of Rab2-GFP (compare (Fig. 3.13 B (A-C) and Fig. 3.13 B
(D-F)).
This data further corroborate the recruitment of both ICA69 and Rab2 to the intermediate
compartment.
Additional immunocytochemistry experiments were performed upon treatment of INS-1
cells with BrefeldinA (BFA) (Fig. 3.14). BFA, which is synthesized by a variety of fungi,
inhibits guanine-nucleotide exchange on ARF1 and consequently prevents the binding of COPI
proteins to the Golgi membranes. This, in turn, causes the loss of the Golgi structure, with
the redistribution of Golgi enzymes to the ER, while Golgi matrix proteins, such as GM130,
remain associated with punctate cytoplasmic structures called “Golgi remnants” (234).
Following treatment of INS-1 cells with BFA (3 µg/ml, 45 min), the signals of both ICA69
(Fig. 3.14 D-F and J-L) and Rab2-GFP (Fig. 3.14 K-L) decreases, consistent with their re-
distribution in the cytosol and their dependence on the integrity of the ER and the Golgi
complex.
3.7 Functional studies on ICA69
The data reported above point to ICA69 as a downstream effector of Rab2. Studies were
conducted and are currently ongoing to test whether the phenotype resulting from the over-
expression of ICA69 over-expression resembles that observed upon the over-expression of Rab2,
and investigate in such way ICA69 function. To this aim, a plasmid encoding full length ICA69,
tagged at its N-terminus with the X− pressTM epitope and the poly-histidine tag followed by
glycin, was generated. As shown in Fig. 3.15, this tagged form of ICA69, called ICA69-HisMAX,
is expressed in INS-1 cells, and is detectable by antibodies directed either against ICA69 or one
of the two tags.
63
3.7 Functional studies on ICA69
Figure 3.14: ICA69 distribution upon incubation of INS-1 cells with BFA
Confocal microscopy images from INS-1 cells (A-F) or INS-1 cells transfected with pEGFP-Rab2
(G-L). Cells were incubated or not with BFA, as indicated. A, D, G and J: immunolabeling
for ICA69 (pseudored). B and E: immunolabeling for GM130 (pseudogreen). H and K: GFP
fluorescence (pseudogreen). C, F, I, L: merge. Scale bar: 5 µm.
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αICA69 αXpressWB:
NT  T NT  T
Figure 3.15: Expression of ICA69-HisMAX in INS-1
Western blotting on Triton X-100 soluble fraction of INS-1 cells (NT) (lanes 1 and 3) or INS-1
transfected with a plasmid encoding the ICA69-HisMAX (T) (lanes 2 and 4), with the polyclonal
α-ICA69 and an α-X− pressTM antibody.
3.7.1 ICA512 conversion
The effect of ICA69 or Rab2 over-expression on the early secretory pathway was analyzed by
examining the conversion of pro-ICA512 into the mature form of the protein1.
To this aim, control INS-1 cells or INS-1 over-expressing Rab2, ICA69 or ICA69woBAR
were kept at rest for 1 hour, stimulated for 30 min to induce the biosynthesis of pro-ICA512,
and then returned to resting medium, for up to 1.5 hours, in order to follow its conversion in
the mature form while trafficking from the ER to the SGs, through the Golgi.
The result of this experiment is shown in Fig. 3.16. Stimulation of control cells induces an
increase in the levels of pro-ICA512 (compare R and S), which is progressively converted in
the mature form, with consequent consumption of pro-ICA512. Ninety min after stimulation,
cells are depleted of both the pro-form and the mature form of ICA512. In cells over-expressing
Rab2-GFP, instead, the levels of pro-ICA512 do not change in the course of the experiment.
Likewise the levels of ICA512-TMF remain constant after the stimulation, though its levels are
strongly diminished if compared with those of control cells. In cells over-expressing ICA69, this
effect is amplified. The amount of pro-ICA512 is indeed increased, as only a smaller fraction of
1ICA512 is a N-glycosilated T1D autoantigen investigated in the laboratory were this thesis was carried
on. Pro-ICA512 is synthesized as a glycoprotein of 110 kDa. Along the secretory pathway pro-ICA512 is first
converted into a protein of 130 kDa, with a very short half-life, and then during the maturation of the SG from
the Golgi towards the plasma membrane, is cleaved at a consensus site for furin-like convertase. The resulting
transmembrane fragment (ICA512-TMF) has a molecular weight of ∼70 kDa (235).
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Figure 3.16: ICA512 maturation upon Rab2 or ICA69 over-expression
Western blotting on Triton X-100 soluble fraction of INS-1 cells (up, left) or INS-1 trans-
fected with a plasmid encoding Rab2-GFP (up, right) or ICA69-HisMAX (bottom, left) or
ICA69woBAR (bottom, right). Cells were at rest (R) in resting medium (no glucose, 5 mM
potassium) for 1.5 hours, or at rest for 1 hour and stimulated with high glucose (25 mM) and
high potassium (55 mM) for 30 min (S), or at rest for 1 hour, stimulated for 30 min, and
returned in resting medium for the time indicated, up to 90 min. The antibodies used for the
western blotting are also indicated.
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the protein is converted into ICA512-TMF. In cells over-expressing the C-terminus of ICA69,
the rise in pro-ICA512 levels and its reduced conversion in the mature form of the protein, are
intermediate between the two last cases.
These data point to a partial block in the trafficking of ICA512 beyond the Golgi complex
upon over-expression of Rab2, ICA69 or ICA69woBAR.
3.7.2 Insulin secretion
The over-expression of Rab2 correlates, even if not unequivocally, with a partial block of the
trafficking between ER and Golgi (62). To investigate whether Rab2 or ICA69 over-expression
determine an alteration of trafficking in β-cells, insulin secretion was measured in control (not
transfected) INS-1 cells or in INS-1 cells over-expressing Rab2 or ICA69. As indicated in
Fig. 3.17, the over-expression of Rab2 correlates with ∼28% decrease in glucose stimulated
insulin secretion, while the over-expression of ICA69 correlates with a ∼11% decrease in insulin
secretion upon stimulation of the cells.
Figure 3.17: Insulin secretion upon Rab2 or ICA69 over-expression
Insulin secretion in INS-1 cells, measured as stimulation index upon stimulation of the cells
with 25 mM glucose and 55 mM potassium for 2 hours, as described in Materials and Methods.
Grey: control cells (not transfected). Blue: cells over-expressing Rab2-GFP. Red: cells over-
expressing ICA69-HisMAX. The quantification refers to three independent experiments. Not
transfected cells were equaled to 100%. The error bar indicates the SD for the not transfected
cells, equaled to 100% and the SE for transfected cells.
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Therefore, ICA69 over-expression appears to impair insulin secretion from INS-1 cells, even
if less than Rab2 over-expression.
3.7.3 Recruitment of β-COP on membranes
Previous data in the literature indicated Rab2 over-expression being coupled with an increase in
membrane-associated β-COP, more in detail with an increase in vesicle-associated β-COP, and a
decrease in ER, IC and Golgi-associated β-COP. These data suggested therefore a role for Rab2
in the formation of COPI-vesicles from the IC (229; 236). To investigate whether this effect
was reproducible, the same subcellular fractionation protocol described in (236) was applied to
control (not transfected) INS-1 cells or INS-1 cells transfected with a plasmid encoding Rab2-
GFP or ICA69-HisMAX. Briefly, post nuclear supernatants (PNS) where subjected to sequential
centrifugation at 20, 000× g and 100, 000× g. The first pellet (P1) contains rapidly sedimenting
membranes (ER, IC and Golgi compartments), while the second pellet (P2) contains vesicles.
The results of this experiment are reported in Fig. 3.18. At variance with the data obtained
in HeLa or Normal Rat Kidney (NRK) cells (236), Rab2 over-expression correlates with an
increase of ER, IC and Golgi-associated β-COP (Fig. 3.18 C, compare P1-NT with P1-Rab2),
and a decrease in the vesicle-associated β-COP (Fig. 3.18 C, compare P2-NT with P2-Rab2).
No significant changes were observed in the amount of β-COP in the cytosolic fraction. ICA69
over-expression is coupled with an even larger increase of ER, IC and Golgi-associated β-COP
(Fig. 3.18 C, compare P1-NT with P1-ICA69), and a larger decrease in the vesicle-associated
β-COP (Fig. 3.18 C, compare P2-NT with P2-ICA69). Moreover ICA69 over-expression was
associated with an increase of β-COP in the cytosolic fraction.
These data suggest a similar repartitioning of β-COP following the over-expression of Rab2
or ICA69, with a redistribution between fast sedimenting membranes, vesicles and cytosol which
is more pronounced upon over-expression of ICA69 than upon over-expression of Rab2.
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Figure 3.18: β-COP distribution in different cellular fractions uopn Rab2 or ICA69
over-expression
A) Subcellular fractionation was performed on INS-1 or INS-1 transfected with pEGFP-Rab2,
or pcDNA4/HisMAX-ICA69 as described in Materials and Methods. Followed SDS/PAGE and
western blotting with the antibodies indicated. 23, 18 and 7 µg of total protein were loaded on
the gel for P1, P2 and cytosol, respectively. With the α-ICA69 and the α-tubulin antibodies,
the same gel was exposed for either for a short or long period of time for the acquisition of
the signal. B) PNS from INS-1 or INS-1 transfected with pEGFP-Rab2, or pcDNA4/HisMAX-
ICA69, subjected to SDS/PAGE, followed by western blotting with the antibodies indicated. C)
Quantification of three independent experiments. Amounts were normalized against γ-tubulin.






Through sequence alignments, it was discovered, in mammals, the existence of a novel gene
encoding an ICA69 orthologue/paralogue1, henceforth termed ICA69 Related Protein (ICA69-
RP). ICA69-RP gene is located in position 2q33.1 in humans, 1c2 in mice and 9q31 in rats
(ICA69 is located in positions 7p22, 6A1-A2 and 4q21 respectively, in the same animals).
Both genes are predicted to encode alternatively spliced isoforms in humans, mice and rats, as
indicated in the Ensembl database (http://www.ensembl.org/index.html).
4.1.1 Phylogenetic tree
As a defined secretory phenotype was observed in C.elegans upon mutations of ric19, but
ICA69null mice had no obvious phenotype, there was the possibility ICA69-RP could have been
the real homolog of ric19, being therefore involved in the process of neuroendocrine secretion
via association with secretory vesicles. In order to address this question a phylogenetic tree was
generated.
The tree is reported in Fig. 4.1 and was obtained using ClustalW, a multiple sequence
alignment program, at the European Bioinformatic institute (EBI). According to this analysis,
ICA69 is evolutionary closer to ric19 than ICA69-RP, thereby suggesting the initial hypothesis
was not correct. Partially redundant functions between ICA69 and ICA69-RP or between
1Both paralogues and orthologues are genes related by duplication within a genome. Orthologues retain the













Figure 4.1: ICA69 protein family genealogical tree
Genealogical tree for ICA69 family members in Homo sapiens, Mus musculus, Rattus
norvegicus, Caenorabitis elegans, Drosophila melanogaster and Anopheles gambiae. The
blue rectangle indicates ICA69 paralogues, the red one indicates ICA69 homologs. The tree
shows the relatively small “evolutionary time” (indicated by the length of the horizontal
lines) between ICA69-RP homologs and ICA69 homologs respectively in humans, mice and
rats, and a bigger “evolutionary time” between ICA69 mammalian and not mammalian ho-
mologs. Accession numbers (NCBI): H.sapiens ICA69-RP: NP 612477.3; M.musculus ICA69-
RP: NP 081683.2; R.norvegicus ICA69-RP: NP 955432.1;H.sapiens ICA69: NP 071682.1;
M.musculus ICA69: NP 034622.2; R.norvegicus ICA69: NP 110471.1; C.elegans ric19:
NP 491216.2; A.gambiae ENSANGG00000009015: XP 316657.2.
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ICA69 and some yet unidentified protein, on the other hand, may account for the lack of a
phenotipe in ICA69null mice.
4.1.2 Cloning of ICA69-RP cDNA
According to the SOURCE database (http://source.stanford.edu/cgi-bin/source/sourceSearch)
ICA69-RP was predicted to be highly expressed in brain. Thus, the ICA69-RP cDNA was
cloned by PCR from a rat brain cDNA library. The sequence of the cloned cDNA encodes
a protein of 435 aa, and points to an exon-intron structure of the ICA69-RP gene partially
different from the one deposited at the time in the public databases, and which was generated
by automated computational analysis of the yet incomplete rat genome.
XP_237197 (in silico)
1 2 7 8 93 54 6 1011 12 13 14
1 2 4 5 7 8 9 10
NM_199400 (from cDNA)
113 6
Figure 4.2: ICA69-RP gene structure
Exon-intron structure of ICA69-RP gene (on the top) as deduced by sequencing the cDNA
obtained from a rat brain cDNA library, and now deposited in the public database. It differs
from the predicted structure of the gene derived by automated computational analysis (on the
bottom). The red crosses indicate exons which are missing in the new structure. The light
blue rectangles are regions found to belong to the coding sequense and not to introns. The red
rectangle is a sequence found to belong to an intron and not to the coding sequence.
The differences between the two gene structures are reported in Fig. 4.2. More in detail:
• exon 2 extends 19 nucleotides before the predicted 5’ site
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• exons 3 ,6 and 11 of the old structure are missing
• exon 9 extends 201 nucleotides before the predicted 5’ site and 2 nucleotides after the
predicted 3’ site
• exon 11 extends 51 nucleotides after the predicted 3’ site
The coding sequence of rat ICA69-RP, as predicted by the rat genome sequencing project,
contained several large gaps compared to human and mouse ICA69-RP. The experimental data
did not confirm anymore the original prediction. The comparison of ICA69-RP amino acidic
sequences in these species, as present nowadays in the public databases, is reported in Appendix
A .
4.2 ICA69-RP versus ICA69
Both ICA69 and ICA69-RP genes are predicted to encode alternatively spliced isoforms in
humans, mice, and rats. In reference to the most common isoforms, ICA69-RP includes 482 aa
in humans (predicted MW: 54 kDa), 431 aa in mice (predicted MW: 49 kDa), and 435 aa in
rats (predicted MW: 50 kDa). As illustrated in table 4.1 and table 4.2, ICA69 and ICA69-RP
are highly conserved among humans, mice and rats, and between each other.
ICA69 ICA69-RP
% similarity within the homologs 97.0 % 93.0 %
% identity within the homologs 88.5% 76.5 %
Table 4.1: ICA69-RP in human, mouse and rat
human mouse rat
% similarity within the paralogs 96.8% 75.5% 79.0 %
% identity within the paralogs 47.8% 50.0% 52.0 %
Table 4.2: ICA69-RP versus ICA69
More in detail (Fig. 4.3 and AppendixA), ICA69 and ICA69-RP are highly conserved in
their N-terminal region (first 250 aa) containing a BAR domain which is almost identical in
ICA69 and ICA69-RP, and in the C-terminal region (last 22 aa), while they are quite divergent
in the central region, with two gaps of 22 and 9 aa respectively in ICA69-RP, compared to
ICA69.
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ICA69
ICA69-RP
Figure 4.3: Schematical representation of ICA69 and ICA69-RP
The cartoon in relative to ICA69 and ICA69-RP proteins. The helix indicates the N-terminal
BAR domain. The cyan, at the N-terminal and C-terminal of the two proteins, encompassing
also the BAR domain, indicates high homology regions; the red and the blue indicate the regions
were ICA69 and ICA69-RP, respectively, differ the most.
4.3 ICA69-RP tissue expression
4.3.1 Rat tissues
In order to study the tissue expression of ICA69-RP, RT-PCR analyses were performed on RNA
prepared from various rat tissues (Fig. 4.4). The data obtained1 indicate that both ICA69 and
ICA69-RP are expressed in brain and pancreatic islets, with much higher expression levels in
brain. Interestingly it is possible to detect ICA69-RP but not ICA69 expression in the hearth.
Furthermore, ICA69-RP cDNAs in hearth and brain are slightly different in size, suggesting a
differential tissue expression of ICA69-RP isoforms, which however was not further investigated.
4.3.2 Human tissues
RT-PCR analyses were performed on various total human RNA purchased from BD Bioscience.
The data obtained (Fig. 4.5), which are consistent with those in the SOURCE database, indicate
that ICA69-RP is expressed mainly in the brain, including the cerebellum, in the testis and in
the spinal cord.
Taken together these data indicate that ICA69-RP has the typical distribution pattern of
genes that are preferentially expressed in neuroendocrine cells.
1Ins indicate the rat insulinoma cell line INS-1. The results of the RT-PCR from this cells will be discussed
in section 4.4 on page 76.
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Figure 4.4: ICA69-RP expression in rat tissues
Semi-quantitative RT-PCR analysis on RNA prepared from various rat tissues. Br=Brain,
Lu=Lung, He=Hearth, Ki=Kidney, Li=Liver, Mu=Muscle, Sp=Spleen, Ins Rest=INS1 cells
in resting conditions, INS Stim=INS1 cells stimulated with high glucose, Is=Islets. ICA69,






















































































Figure 4.5: ICA69-RP expression in human tissues
Semi-quantitative RT-PCR analysis on total human RNA from the tissues indicated, as pur-
chased from BD Biosciences. Segments of approximately 150 bp for both ICA69-RP and the
house keeping gene β-actin respectively, were PCR-amplified.
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4.4 ICA69-RP glucose regulation
Fig. 4.4 suggested a glucose regulation of ICA69-RP. Iits mRNA increased upon stimulation
of INS-1 cells with high glucose (25 mM) for two hours (compare INS Rest and INS Stim
in Fig. 4.4, top panel) . As already described in section 1.4.3 on page 36 regarding insulin-
containing SGs, glucose is the primary physiological stimulator of insulin secretion. It triggers
SGs exocytosis and activates transcriptional and post-transcriptional mechanisms in order to
upregulate the expression of secretory granule genes and renew granule stores which undergo
depletion following exocytosis. More in detail, increased translation of mRNA accounts entirely
for the up-regulation of SG components biosynthesis within the first two hours after stimula-
tion, typically within 20-30 min from the beginning of the stimulation, whereas activation of
transcription is a slower process (237; 238). The putative glucose regulation of ICA69-RP was
























Figure 4.6: ICA69-RP glucose regulation
A) Semiquantitative RT-PCR analysis from INS-1 cells kept at rest (0 mM glucose) or stim-
ulated (25 mM glucose). B) Quantification of three independent experiments; amounts were
normalized against β-actin. The error bar indicates the SD for the resting condition, equaled
to 100%, and the SE for the stimulated condition.
To further investigate this issue, additional semiquantitative RT-PCRs were performed on
INS-1 cells in resting condition or stimulated for two hours with high glucose (the stimulation
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of the cells also with high potassium was not necessary for the purposes of this experiments,
as it determines depolarization of the membrane and insulin secretion, but does not have any
transcriptional or post-transcriptional effect). Moreover two sets of oligos were chosen to carry
out the RT-PCR experiments, giving a PCR product of 650 and 550 base pairs (bp) respectively.
The results of the experiment relative to the 650 bp PCR product (identical values were obtained
using the other set of oligos) are reported in Fig. 4.6. ICA69-RP mRNA increases 1.55 fold in
INS-1 cells stimulated with high glucose for two hours. These data indicate that ICA69-RP is
glucose-regulated.
Many mRNA encoding proteins of the SGs are stabilized, upon stimulation, through the
binding of the protein polypirimidine tract-binding protein (PTB) to their 5’ or 3’-untranslated
regions: this leads to their increased translation. Bioinformatic searches did not reveal any
putative binding site for PTB. ICA69-RP, however, could also be regulated by glucose but
indipendenly from PTB.
4.5 ICA69-RP antibodies
4.5.1 Production of a polyclonal α-ICA69-RP antibody
In order to obtain α-ICA69-RP specific antibodies a construct expressing a fusion protein
between GST and the amino acids 266-402 of ICA69-RP was generated (Fig. 4.7). The construct
was expressed in bacteria, the GST fusion protein purified (Appendix B, Fig. B.2 on page 113)
and sent to Eurogentec to be injected into rabbits.
As showed in Fig. 4.3 (the blue region in ICA69-RP), the region of ICA69-RP chosen for
the expression in bacteria is the most divergent region from ICA69, and its use as immunogen
in rabbits provided high probability of obtaining antibodies which would not have cross-reacted
with the orthologue/paralogue gene product.
4.5.2 Characterization of the polyclonal α-ICA69-RP antibody
The reactivity of the crude rabbit antisera against ICA69-RP was first evaluated using a fusion
protein between ICA69-RP and GFP (AppendixB, Fig. B.3 on page 114). Briefly, the antibody
was affinity purified and tested by western blotting and immunocytochemistry on INS-1 cells,
human epidermal keratinocytes (HEK cells) and transformed african green monkey kidney








Figure 4.7: Schematic representation of ICA69-RP-antigen
The cartoon indicate the region in ICA69-RP (named ICA69-RP-antigen) which, in fusion with
GST, was used as immunogen to inject rabbits and produce α-ICA69-RP specific antibodies.
By western blotting (Fig. 4.8 A) ICA69-RP-GFP was detected in the Triton X-100 soluble
fraction of cells as a ∼80 kDa protein using an α-GFP antibody or the affinity purified α-
ICA69-RP antibody. Considering the fusion with GFP, which has a molecular weight of ∼27
kDa, this mobility is consistent with the expected size of 50 kDa for ICA69-RP.
By immunocytochemistry the α-ICA69-RP antibody only reacted with cells that were also
positive for GFP (compare Fig. 4.9 A and D with Fig. 4.9 B and E, respectively. Compare also,
in Fig. 4.11 B, A-C (top) with D-F (bottom)), thereby confirming the specific reactivity of this
antibody.
4.5.3 Detection of endogenous ICA69-RP
Despite the encouraging evidences obtained with the above described α-ICA69-RP antibody,
the same did not recognized a bonafide endogenous ICA69-RP by western blotting on Triton
X-100 soluble or insoluble fractions of INS1-cells, grown either in normal medium, or in resting
(0 mM glucose) or stimulating (25 mM glucose, 55 mM KCl) buffers. ICA69-RP was also not
detectable in cells treated with a proteasome inhbitor.
A commercial monoclonal antibody against ICA69-RP, which in the meantime become avail-
able, was also similarly tested. Despite recognizing ICA69-RP overexpressed in cells, this
antibody also failed to detect the endogenous ICA69-RP (Fig. 4.8 B) probably because the
expression levels of this protein in all attempted conditions were too low.
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 Ø = not transfected
GFP = transfected with pEGFP-N1




















































Figure 4.8: Recognition of ICA69-RP by two antibodies: Western Blot
A) Western blotting on HEK cells Triton X-100 soluble fraction with a α-GFP antibody or
with the polyclonal α-ICA69-RP antibody. Lanes 1 and 2: not transfected cells. Lanes 3 and
4: cells transfected with pEGFP-N1. Lanes 5 and 6: cells transfected with pEGFP-ICA69-RP.
B) Western blotting on INS-1 cells Triton X-100 soluble fraction with a α-GFP antibody or
with the commercial monoclonal α-ICA69-RP antibody. Lanes 1 and 2: cells transfected with
pEGFP-N1. Lanes 3 and 4: cells transfected with pEGFP-ICA69-RP. It should be noted that
the α-GFP antibody does not detect GFP (∼27 kDa) in lanes 2 and 4 because the portion of











Figure 4.9: Recognition of ICA69-RP by an affinity purified antibody: Immunocy-
tochemistry
Confocal microscopy images from COS-7 (A-C) and HEK (D-E) cells transfected with pEGFP-
ICA69-RP. A and D: immunolabeling for ICA69-RP (pseudored). B and E: GFP fluorescence
(pseudogreen). C and F: merge - nuclei counterstained with DAPI (pseudoblue). Scale bar: 5
µm.
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4.6 Generation of a cell line expressing ICA69-RP-GFP
Comparable negative results were obtained using both antibodies for visualization of en-
dogenous ICA69-RP in INS-1 cells by immunofluorescence microscopy (data not shown).
4.6 Generation of a cell line expressing ICA69-RP-GFP
To continue investigating the properties of ICA69-RP, while obviating the inability to detect the
endogenous protein, INS-1 cells stably expressing ICA69-RP fused with GFP were generated.
Of several stable ICA69-RP-GFP expressing INS-1 clones originally generated (Fig. 4.10), two











































Figure 4.10: INS-1 ICA69-RP-GFP stable cell line: different clones
Western blotting on Triton X-100 soluble fraction of INS-1 cells stably expressing ICA69-RP-
GFP using the polyclonal α-ICA69-RP antibody. Of all the clones, clone 3 and clone 5 were
further analyzed.
4.6.1 Immunocytochemistry on the stable cell line
Confocal microscopy indicated that ICA69-RP-GFP is mostly cytosolic (Fig. 4.11 A (C and D)
and B (A-C)) and does not significantly colocalize with markers of the ER (PDI), cis-medial
Golgi (GM130), TGN (TGN38), secretory granules (insulin and CPH/E), and synaptic-like
microvesicles (synaptophysin) (data not shown). The staining pattern, however, suggests that
ICA69-RP-GFP may not be entirely soluble. As previously shown for COS-7 and HEK cells
expressing ICA69-RP-GFP, the α-ICA69-RP antibody only reacted, by immunocytochemistry,
with cells positive for GFP (Fig. 4.11 B).
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Figure 4.11: INS-1 ICA69-RP-GFP stable cell line
Confocal microscopy images from INS-1 cells stably expressing GFP or ICA69-RP-GFP. Scale
bar: 5 µm. A) A and B: INS-1 stably expressing GFP. C and D: INS-1 stably expressing ICA69-
RP-GFP. A and C: GFP fluorescence (pseudogreen). B and D: merge (nuclei counterstained
with DAPI (pseudoblue)). B) A-C: INS-1 stably expressing ICA69-RP-GFP. D-F: INS-1 sta-
bly expressing GFP. A and D: immunolabeling for ICA69-RP (pseudored). B and E: GFP




Arfaptin 1 and 2, as well as amphiphysin 1 and amphiphysin 2 homo/heterodimerize and bind
small GTPases through their BAR domain (48; 239). Thus, it was possible that ICA69 and
ICA69-RP would have formed heterodimers. This hypothesis was investigated by performing
immunoprecipitation experiments from insulinoma cells and fibroblasts overexpressing ICA69-
RP-GFP using an α-GFP antibody or the two α-ICA69-RP antibodies and western blotting
















RP: WB with α-ICA69-RP Ab








Figure 4.12: Interaction ICA69/ICA69-RP
Immunoprecipitation experiment from Triton X-100 soluble fraction of INS-1 transiently trans-
fected with ICA69-RP-GFP, using the monoclonal α-ICA69-RP antibody (identical results were
obtained with the polyclonal antibody). Lanes 1 and 2: input (10% of the cell extract used for
the immunoprecipitation). Lanes 3 and 4: immunoprecipitations. The antibodies used for the
western blotting are indicated.
Up to now the attempts to detect an ICA69/ICA69-RP heterodimer did not produce any
positive result.
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4.8 Interaction of ICA69-RP with Rab proteins
Using the same approaches as for ICA69 (section 3.3 on page 50), i.e. immunoprecipitations and
pull- down assays, the possible interaction of ICA69-RP with Rab2 (as in the case of ICA69)
or with Rab1 (the other Rab involved in ER-Golgi transport) was investigated. These assays
did not provide any positive result (data not shown). On the other hand it is possible that





This thesis characterized the two members of ICA69 protein family, ICA69 and ICA69-RP, and
initiated the elucidation of their role in membrane traffic in pancreatic β- cells.
5.1 Focus on ICA69
As outlined in the Chapter 2, several existing lines of evidence point towards a role of ICA69 in
secretion. The two most suggestive results are: the presence of a BAR domain in ICA69, which
is a membrane binding/bending module found in proteins involved in intracellular transport
(48); and the specific secretory phenotype of a C. elegans mutant lacking the ICA69 homologue
(225).
In this thesis it was shown that ICA69 is distributed in a punctuate manner within cells.
ICA69 was found to be more enriched in the perinuclear region, where also markers of the
Golgi region are present. Previous studies failed to demonstrate the association of ICA69 with
regulated secretory vesicles of pancreatic β-cells, including SVs (225) and the insulin-containing
SGs (226). However, this does not exclude the possibility that ICA69 may be involved in earlier
stages of membrane trafficking. The cellular localization of ICA69 as reported in this thesis
supports indeed this hypothesis. Impaired protein transport along the early secretory pathway
may still results in deficient regulated secretion and account for the involvement of ICA69 in
both neurotransmitter secretion, justifying the defective release of acetylcholine in the C. elegans
mutant despite the absence of ICA69 on SVs, and secretion of insulin, a property, this latter,
shared with other autoantigens of T1D.
In this thesis it was shown that ICA69 interacts with several membrane lipids, including
PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3 in a protein-lipid overlay
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assay. In view of the limit of this assay, this data should be taken with caution: for instance,
control binding assays showed a similar broad binding pattern for amphiphysin 1, despite the
fact that this protein is known to interact preferentially with PI(4,5)P2. Yet, the protein-lipid
overlay assay results suggest the possibility that ICA69 binds phospholipids, as expected in
the case of proteins containing a BAR domain. A similar phospholipid binding pattern has
been found with the BAR domain-containing proteins RICH-1 (240) and arfaptin2 (Giovanni
D’Angelo, Consorzio Mario Negri Sud,-Italy, personal communication). In particular, the BAR
domains of ICA69 and arfaptin 2 are very similar and both proteins appear to interact prefer-
entially with PI(4)P. This phosphoinositide, in turn, is enriched on the Golgi complex and is
required for the budding of secretory vesicles from this compartment (121). The work presented
herein supports the emerging picture that ICA69 associates with Golgi membranes (226).
In this thesis several biochemical and imaging techniques were applied to investigate the
interaction between ICA69 and Rab2. This was motivated by earlier reports of preliminary
data that pointed to the interaction of ICA69 with a small GTPase (226) and a two-hybrid
screening in yeast identified ICA69 as a putative binding partner of Rab2 (F. Barr, personal
communication). Rab2 is a small GTPase that is known to associate with the intermediate
compartment (IC) (232). It is involved in the trafficking between the ER and the Golgi complex,
while Rab1, found in the ER, IC and early compartments of the Golgi complex, plays a role
in the anterograde trafficking between the ER and the Golgi, through COPII vesicle formation
(241). Rab2, in particular, recruits β-COP for vesicle formation (229) and was originally
proposed to participate, as the COPI coat itself, in the retrograde transport between the ER
and Golgi complex1 (242). Several evidence, however, indicate that Rab2 may be involved
also in the anterograde transport (30; 62; 63). With respect to Rab1, Rab2 could therefore
function in a parallel or sequential fashion in regulating the ER-to-Golgi transport (62). Thus
it is apparent that the molecular mechanism of Rab2 action remains unclear, with only few
effectors of Rab2 identified. E. Tisdale and coll., who performed most of the studies on Rab2,
suggested that Rab2 stimulates vesicle formation by enhancing the recruitment of β-COP to
the membranes of the intermediate compartment (229). For this interaction to occur it is
essential that Rab2 binds to its effector protein kinase C PKCι/λ (63). Another Rab2 effector
is glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is believed to be involved in
the trafficking between the ER and Golgi independently of its glycolytic activity (243), even
1The possible function of COPI-coated vesicles in the anterograde transport, as well as in the retrograde
transport, was discussed in the introduction, subsection 1.3.1.2, on page 10.
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though its function in this respect remains unclear. F. Barr and coll., on the other hand,
showed the GTP-dependent interaction of Rab2 with GM1301, GRASPP55 and golgin-45, all
Golgi proteins, and propose a role for the GRASPP55-golgin45-Rab2 complex in anterograde
protein transport and Golgi structure (230).
In this thesis Rab2 was found to co-immunoprecipitate with ICA69 from INS-1 cells extracts.
This approach is usually regarded to be inappropriate for the identification of Rab effectors,
because in the course of the experiment Rab proteins which are not loaded with the non-
hydrolyzable analogue of GTP, GTPγS, would hydrolyze GTP. Thus, the putative interactors
found with this assay, would be considered to bind the Rab protein in their GDP-bound state
and not be considered to be functionally relevant2. Nevertheless, it should also be taken into
account that the hydrolitic activity of diverse Rab proteins may vary. Specifically, Rab2 has a
very slow hydrolytic activity, such that most of it may remain in a GTP-boud state during the
immunoprecipitation procedure (F. Barr, personal communication). Additional Rab effectors
that have been found to co-immunoprecipitate with their respective Rab without addition of
GTPγS include GAPDH with Rab2 (243), as well as Rabaptin4 with Rab4 (244).
In order to substantiate the interaction between ICA69 and Rab2, GST pull down assays
were performed according to the classic procedure described in (245). This analysis demon-
strated the GTP-dependency of this interaction, as the two proteins could interact only when
Rab2 was loaded with GTPγS, but not when loaded with GDP. In similar pull down assays,
this association was shown to be specific. ICA69 did not interact with other Rab proteins, such
as Rab1, Rab4, Rab5 and Rab6.
Additional confirmation of the ICA69/Rab2 interaction was obtained by immunocytochem-
istry experiments. Confocal microscopy showed indeed that ICA69 and Rab2 colocalized ex-
tensively in particulate structures throughout the cytoplasm.
Furthermore the results of two independent experimental procedures suggested that Rab2
recruits ICA69 to membranes. By immunocytochemistry it was found that in cells expressing
the highest levels of Rab2-GFP, and only upon over-expression of Rab2-GFP, ICA69 was en-
riched in a perinuclear structure, where also Rab2-GFP was found. This result suggested a
“redistribution” of ICA69 within the cells that is Rab2 dependent. Furthermore, subcellular
1Surprisingly, the GTP-dependent interaction of Rab2 and GM130 was not reproducible in this thesis, as
pointed out in the Results, subsection 3.3.2, on page 50.
2Rab effectors, as already described in subsection 1.3.5 on page 17, are proteins that only interact with Rabs
in their active, GTP-bound state.
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fractionation studies showed that over-expression of Rab2 correlated with an increased recovery
of ICA69 in the membrane-bound fraction of cell extracts, consistent with a Rab2-mediated
recruitment of ICA69 to membranes.
It is known that by inhibiting nucleotide exchange on ARF1 and thereby preventing the
binding of COPI proteins to Golgi membranes, BFA causes the loss of the Golgi structure,
with the retrieval of the Golgi enzymes into the ER, while Golgi matrix proteins, such as
GM130, remain associated with punctate cytoplasmic structures called “Golgi remnants” (234).
Upon treatment of INS-1 cells with BFA, the signals for both ICA69 and Rab2 were strongly
decreased, consistent with the redistribution of both proteins to the cytoplasm. These results, in
accordance with those on Rab2 (246) and β-COP (234), suggest a similar sensitivity of β-COP,
Rab2 and ICA69 to BFA and point again to the related behavior of ICA69 and Rab2.
Taken together, the results shown in the thesis suggest that Rab2, in its GTP-bound form,
recruits ICA69 to a membrane compartment. It could be that this compartment is the inter-
mediate compartment, where anterograde and retrograde transport first segregate from each
other (63). Additional evidence supporting this hypothesis was obtained by immunostaining of
INS-1 cells incubated at 15 ◦C for 80 min. The incubation at this reduced temperature blocks
the transport between the ER and the Golgi complex, and leads to the accumulation of the in-
termediate compartment, thereby facilitating its visualization (233). In these conditions ICA69
accumulated in perinuclear structures resembling those observed upon over-expression of Rab2.
The appearance of this structures following the 15 ◦C-block, suggests, but do not conclusively
prove, their identity as the intermediate compartment. Notably however, the morphology of
the perinuclear structures where Rab2-GFP accumulated in cells kept at 37 ◦C and the perin-
uclear structures where ICA69 was found in cells incubated at 15 ◦C differ. Thus, it cannot
be excluded that at physiological temperature the bulk of Rab2 and ICA69 may be associated
with structures distinct from the intermediate compartment.
The BAR domain of arfaptin, the first one been solved, was crystalized as a dimer (118).
In general, proteins including a BAR domain are thought to form homodimers as well as het-
erodimers with their close paralogues (48). Similar to previous work on proteins with a BAR
domain (239; 247; 248), two different approaches were used in the course of this thesis to at-
tempt the detection of ICA69 homodimers: comparisons between native and denaturing gels
or co-immunoprecipitations of the endogenous ICA69 and a tagged form of it. Both attempts,
however, were unsuccessful (data not shown). Thus, additional information concerning the
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possible dimerization of ICA69 may come from crystallographic or equilibrium density ultra-
centrifugation studies, as reported for other proteins containing a BAR domain (48; 118; 249).
Moreover, it should be considered that the dimerization constants found in the case of some
proteins with a BAR domain suggest that these proteins mostly exist as monomer in the cell,
while forming dimers only transiently, when associated with membranes (50).
As already described in the Introduction (subsection 1.3.4 on page 15), the cytoskeleton has
an important role in vesicle transport. Kinesin has been shown to be the motor involved in
the microtubule-mediated retrograde transport between the Golgi and the ER (83). Yet, the
molecular connection between kinesin and COPI vesicles is still unknown. In the course of this
thesis it was tested therefore whether ICA69, recruited on membranes by the active form of
Rab2, was also associated with kinesin. Immunoprecipitation experiments, however, did not
provide any evidence this interaction (data not shown).
Preliminary data by two-hybrid screening in yeast indicated that ICA69 binds to Rab2
through its C-terminal region (F. Barr, personal communication), rather than through its BAR
domain. This finding is quite surprising, since the BAR domain usually acts as a binding inter-
face for different GTPases (113; 118; 119). On the other hand, this raises the possibility that
ICA69 acts as a scaffold protein that interacts independently with two small GTPases, through
its BAR domain and its C-terminal region, thereby mediating a cross talk between such GT-
Pases and their associated pathways. However, GST pull down assays failed to demonstrate the
interaction of Rab2 with a truncated mutant containing only the C-terminal region of ICA69.
It is possible, anyway, that the C-terminal domain of ICA69, when expressed alone, is either
not properly folded or anyway not functional, and thus cannot bind to Rab2 in absence of the
remaining part of the protein. Additional experiments will be necessary to conclusively map
the domain of ICA69 that binds to Rab2. Studies are ongoing to test whether the interaction
ICA69/Rab2 actually occurs through the BAR domain of ICA69. However, all attempts to
express the N-terminal half of ICA69 have so far been unsuccessful. If the binding to Rab2
occurrs through the C-terminal domain of ICA69, it would be interesting to test whether the
BAR domain of ICA69 can in turn bind another small GTPase. The interaction between ICA69
and ARF1 has already been tested, with negative result (data not shown). This candidate gene
approach for the identification of small GTPases binding to ICA69 could be extended by per-
forming immunoblots of proteins co-immunoprecipitating or pulled down together with ICA69.
Attention would be placed on GTPases that are localized in the ER and Golgi region. These
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include Arl1, which is important for Golgi structure and function1 (250); Rab33B, which has
a putative role in intra-Golgi trafficking (251); Rab30, which is Golgi-associated (252); and/or
Sar1p, that is required for the formation of COPII-coated vesicles (69). An alternative unbi-
ased approach could be to use recombinant ICA69-GST for large-scale affinity chromatography
and subsequent screening of the eluate for small GTPases and other potential interactors, by
western blotting and mass-spectrometry.
As pointed out earlier, Rab effectors are defined as proteins that interact with the GTP-
bound form of a Rab protein and transduce the signal of the Rab protein in the transport
mechanism (88). To investigate whether ICA69 was actually a novel Rab2 effector, and to
initiate to dissect ICA69 function, several approaches were used. In all cases it was evaluated
whether ICA69 over-expression resembles that of Rab2, therefore suggesting their belonging to
the same pathway.
Results reported previously, indicated that Rab2 over-expression leads to a decrease of 25%
in the processing of the glycoprotein VSV-G from an endoglycosidase H-sensitive form to an
endoglycosidase H-resistant form. Endo H-sensitive species are those present in the ER and
carrying an high mannose precursor oligosaccharide, while endo H-resistant species are those
present in the Golgi and at the plasma membrane (62; 236).
In this thesis the conversion of the pro-form of the T1D autoantigen ICA512 from an endo
H-sensitive to an endo H-resistant form was investigated in control cells and in cells over-
expressing Rab2 or ICA69 (data not shown). This approach, however, was unsuccessful, as
even in the control cells, it was not possible to detect the endo H-resistant form of pro-ICA512.
The very rapid conversion of 130 kDa endo H-resistant pro-ICA512 into ICA512 TMF in the
Golgi complex, as pointed out in section 3.7.1 on page 65, explains this result, while indicating
the inappropriateness of the chosen glycoprotein. In future studies a different protein, such as
VSV-G, should be used for this type of analysis.
To evaluate the effect of ICA69 and Rab2 over-expression on the transport along the se-
cretory pathway a different approach was therefore used. Specifically, the conversion of the
pro-form of ICA512 in the mature form (ICA512-TMF) was analyzed in cells in which the
expression of ICA512 was induced by glucose only for a short time (pulse) (235) and that were
subsequently placed in resting buffer for various periods of time (chase). Control cells showed
an increase in the levels of pro-ICA512 upon stimulation, which decreased over time because
1ARF1 and Arl1 share some common effectors, and have patially overlapping functions.
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of its conversion to ICA512-TMF. Cells over-expressing Rab2 exhibited over the time a con-
stant amount of the pro-form of ICA512, which was most likely less converted into the mature
form. The levels of ICA512-TMF, conversely, decreased when compared with control cells.
These data indicate a partial impairment in the Golgi trafficking of ICA512 upon Rab2 over-
expression. Strikingly, this effect was magnified upon ICA69 over-expression, with an increase
of pro-ICA512 levels over time, and a corresponding decrease in the levels of ICA512-TMF.
These results confirm that ICA69 and Rab2 are involved in the same pathway, and identify
ICA69 as a transducer of Rab2 signaling.
Furthermore, the over-expression of the C-terminus of ICA69 led to an increase in the levels
of pro-ICA512 and a decrease in the levels of ICA512-TMF that were intermediate between
those observed by over-expression of Rab2 or ICA69. While it was not possible to demonstrate
the interaction between the C-terminal region of ICA69 and Rab2 in vitro, it can not be excluded
that the C-terminal region of ICA69 does indeed function as a translator of the effects of Rab2.
Both Rab2 and ICA69 over-expression correlated with an impaired insulin secretion, with
a decrease of 28% in insulin secretion upon Rab2 over-expression, and a more confined 11%
decrease in insulin secretion upon ICA69 over-expression, indicating an alteration in the traf-
ficking in β-cells following their over-expression. Although these decreases are limited in size,
they are likely to be informative because of their high reproducibility.
To further investigate whether the phenotype resulting from the over-expression of ICA69
resembled that observed upon over-expression of Rab2, subcellular fractionation experiments
according to the procedure described in (236) were performed. Contrary to the data reported
in the literature (236), Rab2 over-expression correlated with an increased association of β-COP
with fast sedimenting membranes (conceivably ER, IC and Golgi), and a decreased association
of β-COP with slow sedimenting membranes (conceivably vesicles). Notably, this phenotype
was even more pronounced upon ICA69 over-expression. Furthermore, ICA69 over-expression,
unlike Rab2 over-expression, correlated with an increase in β-COP levels in the cytoplasm.
Published data indicate a role for Rab2 in the recruitment of the coatomer and the stimulation
of vesicle formation from the intermediate compartment (229; 236). The data obtained here
did not allow to establish a correlation between Rab2 or ICA69 with β-COP, and thus to COPI
vesicles. This conclusion is supported by the immunocytochemistry data, which did not show
an overlapping distribution between β-COP and Rab2 or ICA69 in INS-1 cells.
Taken together, the functional studies presented here indicate that the effects of ICA69
over-expression resemble and in some cases amplify those observed in Rab2 over-expressing
91
5.2 Focus on ICA69-RP
INS-1 cells. They conclusively identify ICA69 as a novel effector of Rab2, and therefore may
contribute to the understanding of the still poorly characterized mechanism of action of Rab2.
5.2 Focus on ICA69-RP
The second part of this thesis focused on an ICA69 paralogue, called ICA69-RP. As with
each novel gene, some descriptive work was required before more-in-depth biological questions
could be addressed. The chromosomal location for ICA69-RP in humans, mice and rats was
investigated. ICA69-RP cDNA was cloned from a cDNA library, and the exon-intron structure
of the relative gene was deduced, pointing to a coding sequence for this gene partially different
from the sequence deposited at the time in the public databases, and now replaced by the new
one.
The defective neurotransmitter secretion upon mutation of ric19, a putative ICA69 homo-
logue in C. elegans (225), and the lack of a defined (secretory) phenotype in ICA69null mice
(228), led to the hypothesis that ICA69-RP could be the real homologue of ric19, being there-
fore involved in neuroendocrine secretion. However, analysis of a genealogical tree generated
with several members of the ICA69-protein family in different species showed that this was not
the case. Partially redundant functions between ICA69 and ICA69-RP or between ICA69 and
some yet unidentified protein, on the other hand, may account for the lack of a phenotype in
ICA69null mice.
ICA69-RP tissue expression was investigated, both in rat and human tissues. ICA69-RP
mRNA was detected primarily in neuronal tissues such as total brain, cerebellum and spinal
cord, in pancreatic islets and in the testes (consistent with the reported similarity between
human brain and testis gene expression patterns (253)). These results, in accordance with
the SOURCE databases (http://source.stanford.edu/cgi-bin/source/sourceSearch) reflect the
expression pattern of a gene preferentially expressed in neuroendocrine cells, as already found
in the case of ICA69 (215; 218).
Unlike ICA69, ICA69-RP appears to be glucose regulated. Its mRNA increases 1.55 fold
in INS-1 cells stimulated with 25 mM glucose for two hours. This is a characteristic shared
by many genes associated with the secretory machinery of β-cells. For example, after two
hours of glucose stimulation, insulin mRNA increases 1.43 fold, and ICA512 mRNA increases
∼2.3 folds (185). It is known that glucose stimulation of β-cells prompts the activation of
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post-transcriptional mechanisms1 in order to quickly up-regulate the expression of secretory
granule genes and consequently renew granule stores. This is achieved in part by increasing
the stability of mRNAs encoding SGs components through a mechanism involving the mRNA
binding protein PTB (185) (as detailed in section 1.4.3 on page 36), and in part by up-regulating
the expression and/or activity of factors involved in the expression and transport of molecules
along the secretory pathway. The increased expression of ICA69-RP upon glucose stimulation
of cells may be part of this process.
Unfortunately, all attempts of investigating the intracellular localization of endogenous
ICA69-RP, either with a commercial antibody or with an antibody produced in the course
of this thesis, failed, probably because of the low expression levels of the protein. Insights into
the localization of ICA69-RP could also not be obtained by over-expressing a fusion protein
between ICA69-RP and GFP. In transfected cells ICA69-RP-GFP appears to be mostly cy-
tosolic, with no significant enrichment in any particular compartment. The differences in the
staining obtained for ICA69-RP-GFP and for GFP suggest that ICA69-RP may not be entirely
soluble. Unlike in the case of ICA69, however, a punctate “vesicular” staining, could not be
readily discerned. Subcellular fractionation studies are in progress to address this question.
Using the same approaches as for ICA69, ICA69-RP did not show any interaction either with
Rab2 or Rab1, which are involved in ER-to-Golgi transport. It is thus possible that ICA69-RP
interacts with Rab proteins other then these, or in general with a different small GTP-binding
protein.
To this date, there is no indication that ICA69-RP binds a small GTPase. In order to
investigate this possibility, it would be interesting to immunoprecipitate ICA69-RP-GFP from
transfected cells and then perform GTP overlay assays on the co-immunoprecipitated material.
Unlike in the case of ICA69, a candidate gene approach for the identification of ICA69-RP
interactors may not be recommended, given the broad cytosolic distribution of ICA69-RP-GFP.
An alternative approach would be to use recombinant ICA69-RP-GST for large-scale affinity
chromatography and consequent search in the eluate of small GTPase by mass-spectrometry.
As in the case of ICA69, preliminary information about physiological interactors may also be
obtained by two-hybrid screening in yeast.
1Post-transcriptional mechanisms account entirely for the up-regulation of SGs genes within the first 2 hours





Rat insulinoma INS-1 cells were grown in RPMI 1640 medium (with L-glutamine) (Gibco-Brl
or PAA Laboratories GmbH) supplemented with 10 mM HEPES (MERK KGaA) pH 7.4, 10%
heat-inactivated fetal bovine serum (FBS) (Gibco-Brl or PAA Laboratories GmbH), 2 mM
L-glutamine (PAA Laboratories GmbH), 100 U/ml penicillin (PAA Laboratories GmbH), 100
µg/ml streptomycin (PAA Laboratories GmbH), 1 mM sodium pyruvate (PAA Laboratories
GmbH) and 50 µM 2-mercaptoethanol (Sigma Chemical Co.) (254) and incubated at 37 ◦C in a
humidified 95% air-5% CO2 atmosphere. For trypsinization, cells were separated by exposure to
0.5 mg/ml trypsin-EDTA (PAA Laboratories GmbH) in phosphate buffer saline (PBS) (Gibco-
Brl or PAA Laboratories GmbH) for 3 minutes (min) at room temperature (RT). Trypsin was
inactivated by adding the growth medium indicated above. Cells were usually passaged every
4 days, and medium was changed 2 days after splitting.
For stimulation experiments, and unless otherwise stated, cells were pre-incubated in resting
buffer (5 mM KCl, 120 mM NaCl, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, 1 mg/ml
ovalbumin, 15 mM HEPES pH 7.4) for 1 hour at 37 ◦C. The cells were then incubated for
additional 2 hours at 37 ◦C in resting buffer or in stimulating buffer (25 mM glucose, 70 mM
NaCl, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, 1 mg/ml ovalbumin, 15 mM HEPES pH
7.4, w/o 55 mM KCl, depending on the purposes) (235).
For the time-course stimulation, cells were pre-incubated in resting buffer for 1 hour at 37 ◦C.
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The cells were then incubated for additional 30 min at 37 ◦C in resting buffer or in stimulating
buffer (25 mM glucose, 55 mM KCl), and then, only the latter, in resting buffer for 15, 30, 45,
60 or 90 min.
Human Epidermal Keratinocytes (HEK) cells and Transformed African Green Monkey Kid-
ney Fibroblast Cells (COS-7) cells were grown in Dulbecco’s modified Eagle’s minimal essential
medium (DMEM) (with L-glutamine, 1,000 mg/L D-glucose, sodium pyruvate) (Gibco-Brl)
supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin and 100 µg/ml strepto-
mycin (255; 256) and incubated at 37 ◦C in a humidified 95% air-5% CO2 atmosphere. For
trypsinization cells were washed once with PBS and separated by exposure to 0.025% trypsin-
EDTA in PBS for 4-5 min at RT. Trypsin was inactivated by adding the growth medium
indicated above. Cells were usually passaged every 3 days.
Cells were grown in 175 and 75 cm2 flasks or 6-well plates (BD FalconTM - BD Biosciences).
6.1.1 Transfection
Cells were counted using a Neubauer hemacytometer (Reichert).
INS-1 cells were electroporated with an Amaxa nucleoporator (Amaxa Biosystems, Inc.)
using the Cell line nucleofector kit V (Amaxa Biosystems, Inc.) and the program T-20 (trans-
fection efficiency ∼50%) according to the manufacturers protocol. 4× 106 cells were electropo-
rated with 4 µg of plasmid DNA (unless otherwise stated), then gently resuspended in 2 wells
of a 6-well plate containing 2 ml of the growth medium indicated above and grown for 3-4 days
before harvesting. INS-1 cells stably expressing GFP were selected with 600 µg/ml gentamicin
(Gibco-Brl) and cloned by limiting dilution. INS-1 cells stably expressing ICA69-RP-GFP were
selected with 500 µg/ml gentamicin and cloned by limiting dilution. Two clones expressing high
and low levels of ICA69-RP-GFP, as assessed by western blotting, were further characterized.
During the last period of the thesis, INS-1 cells were occasionally electroporated with a Labo-
ratory Pulse Agile R© Electroporation System, model PA-3,000 (Cytopulse Sciences, Inc.) using
the Cytoporation media (formula T) kit (Cytopulse Sciences, Inc.), at 580 Volt (V), 2 x (4 x
300 µsec (0.2 sec pause)) (1.5 min pause) (transfection efficiency ∼25%); the same number of
cells, amount of DNA and conditions for resuspension indicated above were applied.
HEK and COS-7 cells were transfected using FuGENE 6 transfection reagent (Roche Diag-
nostic GmbH) according to the manufacturers protocol. For each well of a 6-well plate 2.5× 105




The insulin content in cells and in medium (resting or stimulation buffer) was measured wit
the Sensitive Rat Insulin Radioimmunoassay (RIA) Kit (Linco Reseach, Inc.) according to the
manufacturer’s recommendations. Cell proteins were extracted upon incubation in acid-ethanol
(75% EtOH, 1.5% concentrated HCl, 23.5% H2O overnight at −20 ◦C. The stimulation index
















%IR = % Insulin secreted (in resting or stimulated conditions)
Istim = Secreted insulin in stimulating buffer (ng/ml)
ICstim = Cell insulin content in stimulated cells (ng/ml)
Irest = Secreted insulin in resting buffer (ng/ml)
ICrest = Cell insulin content in resting cells (ng/ml)
The stimulation index from control cells was equaled to 100%.
6.2 Animals
6.2.1 Islets isolation
Pancreatic islets from female Wistar rats, were isolated and cultured (400/60 mm culture dish
(BD FalconTM - BD Biosciences)) as described (257). Briefly, a liberase solution containing
100 µl Liberase RI (Roche Diagnostic GmbH) in 6.5 ml RPMI 1640 was injected in the bile
duct. Dissected pancreas was incubated at 37 ◦C in a water bath shaking every 10 min, for
∼26 min. After washing 3 times with cold wash media (RPMI 1640 supplemented with 10%
FBS) islets were filtered through a cell dissociation sieve, collecting the flow through. The
pellet after centrifugation was resuspended in Histopaque 1077 (Sigma Chemical Co.), applied
on a gradient generated by 12 ml Histopaque overlayed by 13-14 ml of cold RPMI 1640, and
centrifuged at 2,400 rpm for 20 min at 10 ◦C in a Heraeus Multifuge KS-R centrifuge (Kendro
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- Thermo Electron Corp.). The interface layer was collected, washed with cold RMPI 1640
and resuspended in RPMI 1640 medium supplemented with 20 mM HEPES pH 7.4, 10% heat-
inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin. Purified islets were hand picked
under a stereomicroscope.
6.2.2 Tissues isolation
Rats were euthanized in agreement with the German Welfare Law and approved by the Gov-
ernment Authority of Saxony. Tissues were excised, flash-freezed in liquid nitrogen and imme-
diately transfered to -80 ◦C.
6.3 Cell extracts
6.3.1 Triton X-100 soluble fraction
Cells were washed twice with ice cold PBS and sedimented by centrifugation at 1,100 rpm for
6 min at 4 ◦C in a Heraeus Multifuge centrifuge. Triton X-100 soluble fraction was extracted
upon incubation of the cells in 50 µl (for 1 well of a 6-well plate) or 800 µl (for a 175 cm2
flask, 90% confluent) of lysis buffer (10 mM Tris-HCl pH 8.0, 140 mM NaCl, 1% Triton X-
100 (Sigma Chemical Co.), 1mM EDTA, 1mM phenylmethylsulfonyl fluoride (PMSF) (Sigma
Chemical Co.), 1% protease inhibitor cocktail (Sigma Chemical Co.)) for 30 min at 4 ◦C and
centrifugation at 25, 000× g for 20 min at 4 ◦C in a centrifuge 5417R (Eppendorf AG).
Protein concentration was assessed with the Bio-Rad Protein Assay Reagent (Bio-Rad Lab-
oratories) or with the BCATM protein assay kit (PIERCE Biotechnology, Inc.) using an Ul-
trospec 3300 Pro spectrophotometer (Amersham Bioscience).
6.3.2 Subcellular fractionation
Two different protocols for subcellular fractionation were applied, to investigate the Rab2 de-
pendent ICA69 membrane recruitment and the β-COP redistribution upon Rab2 or ICA69
over-expression, respectively. According to the first method, cells were washed twice with ice
cold PBS, sedimented and resuspended in 1.5 ml (for a 175 cm2 flask) of homogenization buffer
(0.32 M sucrose in 10 mM HEPES pH 7.5, 1% protease inhibitor cocktail). Cells were homog-
enized with 20 strokes in a ball bearing homogenizer (ball diameter 0.0016 inches, clearance
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0.0012 inches) (H. Issel, Inc.). Cell homogenates were centrifuged at 3, 000× g for 10 min at
4 ◦C in the centrifuge 5417R. 1 ml of the resulting post-nuclear supernatant (PNS) was spun at
150, 000× g for 60 min at 4 ◦C in an OptimaTM MAX Ultracentrifuge (Beckman Coulter, Inc.).
High-speed pellets (HSP) were resuspended to the original volume (1 ml) in homogenization
buffer. According to the second protocol, described in (236), cells were washed twice with ice
cold PBS, sedimented and resuspended in 550 µl (for a 75 cm2 flask) of homogenization buffer
(0.32 M sucrose in 10 mM HEPES pH 7.5, 1% protease inhibitor cocktail). Cells were ho-
mogenized with 20 passes of a 27-gauge syringe. Cell homogenates were centrifuged at 500× g
for 10 min at 4 ◦C in the centrifuge 5417R. 550 µl of the resulting post-nuclear supernatant
(PNS) was spun at 20, 000× g for 20 min at 4 ◦C in the centrifuge 5417R. The pellet (P1) was
resuspended in 100 µl of homogenization buffer, and the resulting supernatant was centrifuged
at 150, 000× g for 60 min at 4 ◦C in the OptimaTM MAX Ultracentrifuge. The so-obtained
pellet (P2) was resuspended in 60 µl of homogenization buffer.
Protein concentration was assessed in both cases with the Bio-Rad Protein Assay Reagent,
as indicated above.
6.4 RNA isolation and reverse transcription
Total RNA was isolated from INS-1 cells or from rat tissues using the RNeasy R© Mini Kit
(QIAGEN, Inc.), following the producer’s instructions. Total RNA from different human tissues
was purchased (Human Total RNA Master Panel II, BD Biosciences). Reverse transcription
was carried out on RNA prepared from INS-1 cells or rat tissues or from human RNA using the
SuperScriptTM RNaseH− reverse transcriptase (Invitrogen Corp.), following the manufacturer’s
recommendations.
6.5 Cloning
6.5.1 Purification of plasmid DNA
Plasmid DNA was purified in large scale (Maxi-prep) and small scale (Mini-prep) using the
EndoFree Plasmid Maxi Kit (QIAGEN, Inc.) and the QIAprep R© Mini-prep Kit (QIAGEN,
Inc.) respectively, following the producer’s instructions. The DNA purity and concentration
were assessed using a Nanodrop ND1000 spectrophotometer (PeqLab Biotechnologie GmbH).
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6.5.2 Restriction enzyme digestion of DNA
Restriction enzyme digestions were performed by incubation the DNA with the appropriate
restriction enzyme(s) (NEB), using 5 units of enzyme per µg of DNA for 2-3 hours at 37 ◦C,
unless a different digestion temperature was indicated. After digestion, the resulting DNA
fragments were separated by agarose gel electrophoresis.
6.5.3 DNA gel electrophoresis
PCR products, DNA inserts and plasmids were run on a suitable agarose gel, stained with ethid-
ium bromide; images of the gels were acquired with GeneGenius BioImaging system (Syngene
- Synoptics Ltd) and quantified, if required, with the GeneSnap software (Syngene - Synoptics
Ltd). When necessary, the desired bands were excised from the gel and DNA was isolated using
a QIAquick R© gel extraction kit (QIAGEN, Inc.) according to the manufacturer’s recommen-
dations.
6.5.4 PCR
The typical reaction mixture for PCR was composed of 50 ng template DNA, 100 pmol forward
and reverse primers, 200 µM dATP, dCTP, dGTP, dTTP, 1X PCR buffer with MgCl2 and 2
units DNA polymerase in H2O (50 µl final volume). Taq DNA Polymerase (Roche Diagnostic
GmbH), Expand high fidelity PCR system (Roche Diagnostic GmbH) or ThermalAceTM (In-
vitrogen Corp.) were used according to the different needs of the PCR experiment. PCRs were
carried out in the thermal cycler Mastercycler epgradient thermal cycler (Eppendorf AG), and
the thermal profile used for the amplification was adjusted in order to obtain a discrete and
clean PCR product. PCR products were purified using the QIAquick R©gel extraction kit or a
QIAquick R© PCR purification kit (QIAGEN, Inc.) according to the manufacturer’s recommen-
dations.
6.5.5 Ligation of DNA
The typical ligation reaction was composed of 100 ng vector DNA, insert DNA (in a ratio 3:1
to the vector DNA), 1X ligase buffer and 1 µl T4 DNA ligase (Invitrogen Corp.) in H2O (50
µl final volume); the reaction was carried out overnight (ON) at 16 ◦C in the thermal cycler.
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6.5.6 Transformation of plasmid DNA
Heat shock transformation of XL10−Gold R© Ultracompetent cells (Stratagene) was performed
according to the manufacturer’s recommendations. Heat shock transformation of BL21 cells
was performed as for the XL10-Gold cells, but without addition of β-mercaptoethanol.
6.5.7 Construction of expression vectors
6.5.7.1 pCRII-ICA69-RP
Rat ICA69-RP was amplified from a rat brain 5’-stretch plus cDNA library (Clontech Labora-
tories, Inc.) using the following primers:
RPfor: 5’-CACCATGGATTCCTTTGAGCACCTC-3’
RPrev: 5’-GGCATTCAGAAGCTCGTCATCTGAG-3’
and the program: 94 ◦C, 5 min; 5 x (94 ◦C, 30 seconds (sec) ; 48 ◦C, 30 sec; 72 ◦C, 1 min 30 sec);
30 x (94 ◦C, 30 sec; 57 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever. The
fresh PCR product was cloned in the pCRII− TOPO R© vector, according to the manufacturer’s
recommendations for the TOPO TA Cloning R© kit (Invitrogen Corp.).
6.5.7.2 pEGFP-ICA69-RP
Rat ICA69-RP was amplified from the pCRII-ICA69-RP using the following primers:
RP-GFPfor: 5’-CGAATTCATGGATTCCTTTGAGCACCTCA-3’
RP-GFPrev: 5’-TGGATCCATGGCATTCAGAAGCTCGT-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 48 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30 x (94 ◦C,
30 sec; 58 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever. The PCR product
was digested with EcoRI and BamHI (NEB), gel purified and subcloned in the plasmid pEGFP-
N1 (Clontech Laboratories, Inc.) digested with the same enzymes and dephosphorylated with
Phosphatase, alkaline (Roche Diagnostic GmbH).
6.5.7.3 pCRII-ICA69






and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 54 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30 x
(94 ◦C, 30 sec; 59 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever. The fresh
PCR product was cloned in the pCRII− TOPO R© vector, according to the manufacturer’s
recommendations of the TOPO TA Cloning R© kit.
6.5.7.4 pGEX-ICA69
ICA69 was amplified from the pCRII-ICA69 cDNA using the following primers:
69GSTfor: 5’-TCTCGAGATGTCAGGACACAAATGTTATT-3’
69GSTrev: 5’-TGCGGCCGCTCATGCATTGAGCAATTCGT-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 56 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30 x
(94 ◦C, 30 sec; 60 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever. The PCR
product was digested with XhoI and NotI (NEB), gel purified and subcloned in the plasmid
pGEX-4T-1 (Amersham Biosciences) digested with the same enzymes and dephosphorylated.
6.5.7.5 pGEX-Amphiphysin1
The cDNA encoding human Amphiphysin1 was excised from the plasmid pcDNA3-HA -Amphi-
physin1 (a gift from P. De Camilli, Yale University, New Haven, USA) using the restriction
enzymes XbaI and BamHI (NEB). Briefly the plasmid DNA was digested with XbaI, purified
using the PCR purification kit, filled in using the ThermalAce polimerase, digested with BamHI,
again purified and subcloned in the plasmid pGEX-4T-1 digested with BamHI and SmaI (NEB)
and dephosphorylated.
6.5.7.6 pGEX-RPantigen
The term “RPantigen” indicates the region in ICA69-RP which was used as immunogen in order
to obtain α-ICA69-RP specific antibodies. RPantigen was amplified from the pCRII-ICA69-RP
using the following primers:
antGSTfor: 5’-TGGATCCACTCCAGGCAATCTCACTG-3’
antGSTrev: 5’-CGAATTCTCAATTGAACCAGGCTGACATGT-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 45 ◦C, 30 sec; 72 ◦C, 1 min); 30 x (94 ◦C,
30 sec; 54 ◦C, 30 sec; 72 ◦C, 1 min); 72 ◦C, 7 min; 4 ◦C, hold forever. The PCR product
was digested EcoRI and BamHI (NEB), gel purified and subcloned in the plasmid pGEX-4T-1




ICA69woBAR Rat ICA69-RP indicates the C-terminal domain of ICA69 (missing the first 253
aa). ICA69woBAR was amplified from the pCRII-ICA69 cDNA using the following primers:
69V5for: 5’-CACCATGTCAGGACACAAATGTTATTCC-3’
69stopV5rev: 5’-TCATCATGCATTGAGCAATTCGTGTTCTT-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 55 ◦C, 30 sec; 72 ◦C, 1 min 20 sec); 30 x
(94 ◦C, 30 sec; 56 ◦C, 30 sec; 72 ◦C, 1 min 20 sec); 72 ◦C, 10 min; 4 ◦C, hold forever. The fresh
PCR product was cloned in the pcDNA3.1D/V5-His vector, according to the manufacturer’s
recommendations the pcDNA3.1Directional TOPO Expression kit (Invitrogen Corp.).
6.5.7.8 pcDNA4/HisMAX-ICA69
ICA69 was amplified from the pCRII-ICA69 cDNA using the following primers:
69Maxfor: 5’-ATGTCAGGACACAAATGTTATTCCTGGG-3’
69Maxrev: 5’-TCATCATGCATTGAGCAATTCGTGTTCTTTA-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 48 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30
x (94 ◦C, 30 sec; 57 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever. The
fresh PCR product was cloned in the pCDNA4/HisMAX− TOPO R© vector, according to the
manufacturer’s recommendations for the pCDNA4/HisMAX− TOPO R© TOPOTACloning R©
kit (Invitrogen Corp.).
6.5.8 Preparation of competent BL21
A single colony of Escherichia Coli coli BL21 was used to inoculate 10 ml of Luria-Bertani
broth (LB medium, (258)) which was grown ON at 37 ◦C with shaking (200 rpm). The day
after the culture was diluted to 100 ml l of LB medium and grown at 37 ◦C with shaking until an
OD600 of 0.25 was measured. Cells were quickly cooled down to 4 ◦C on ice and then collected
by centrifugation at 3,500 rpm for 10 min at 4 ◦C in the Heraeus Multifuge centrifuge; the
resulting pellet was gently resuspended in 40 ml of ice cold TfB1 buffer (100 mM RbCl, 50 mM
MnCl2, 30 mM K-acetate, 10 mM CaCl2, pH 5.8), spun again by centrifugation, resuspended
in 8 ml of TfB2 buffer (10 mM RbCl, 75 mM CaCl2, 10 mM MOPS, pH 6.5, 15% glycerol),





10 % of the first-strand reaction obtained by reverse transcription, obtained as described, was
used for PCR.
6.6.1 Rat tissues
For ICA69 were used the following primers:
ratICAfor: 5’-TCTCGAGATGTCAGGACACAAATGTTATTCC-3’
ratICArev: 5’-ATTGTCGACTCATGCATTGAGCAATTCGTG-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 50 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30 x
(94 ◦C, 30 sec; 59 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever.
For ICA69-RP were used the following primers:
RPfor: 5’-CACCATGGATTCCTTTGAGCACCTC-3’
RPrev: 5’-GGCATTCAGAAGCTCGTCATCTGAG-3’
and the program: 94 ◦C, 3 min; 5 x (94 ◦C, 30 sec; 50 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 30 x
(94 ◦C, 30 sec; 59 ◦C, 30 sec; 72 ◦C, 1 min 30 sec); 72 ◦C, 7 min; 4 ◦C, hold forever.
For β-actin were used the following primers:
actfor: 5’-ACCCACACTGTGCCCATCTA-3’
actrev: 5’-GCCACAGGATTCCATACCCA-3’
and the program: 94 ◦C, 3 min; 30 x (94 ◦C, 30 sec; 55 ◦C, 30 sec; 72 ◦C, 45 sec); 72 ◦C, 7 min;
4 ◦C, hold forever.
6.6.2 Human tissues






and the program: 94 ◦C, 3 min; 35 x (94 ◦C, 30 sec; 56 ◦C, 30 sec; 72 ◦C, 45 sec); 72 ◦C, 7 min;
4 ◦C, hold forever.
For β-actin were used the following primers:
ACTexfor: 5’-GCACCACACCTTCTACAATGAGC-3’
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ACTexrev: 5’-TAGCACAGCCTGGATAGCAACG-3’
and the program: 94 ◦C, 3 min; 30 x (94 ◦C, 30 sec; 58 ◦C, 30 sec; 72 ◦C, 45 sec); 72 ◦C, 7 min;
4 ◦C, hold forever.
6.7 Glucose regulation of ICA69-RP mRNA
10 % of the first-strand reaction obtained by reverse transcription, obtained as described, was
used for PCR.
For ICA69-RP were used the following primers:
BARfor: 5’-GATTCCTTTGAGCACCTCAGA-3’
BARrev: 5’-TTGGGACATCATTTGAGCCGTT-3’
and the program: 94 ◦C, 3 min; 20 x (94 ◦C, 30 sec; 59 ◦C, 30 sec; 72 ◦C, 45 sec); 72 ◦C, 7 min;
4 ◦C, hold forever.
For β-actin were used the following primers:
actfor: 5’-ACCCACACTGTGCCCATCTA-3’
actrev: 5’-GCCACAGGATTCCATACCCA-3’
and the program: 94 ◦C, 3 min; 20 x (94 ◦C, 30 sec; 55 ◦C, 30 sec; 72 ◦C, 45 sec); 72 ◦C, 7 min;
4 ◦C, hold forever.
6.8 Immunocytochemistry
Cells grown on coverslips were fixed with 3% paraformaldehyde (PFA) (MERK KGaA) in 120
mM Na-phosphate pH 7.4 for 20 min at 4 ◦C, washed once with PBS, incubated in quencing
buffer (0.1 M glycin in PBS) for 20 min at RT, washed once with PBS, once with low salt (LS)
buffer (150 mM NaCl, 10 mM Na-phosphate pH 7.4) and twice with high salt (HS) buffer (1M
NaCl, 40 mM Na-phosphate pH 7.4). Unspecific binding sites for the antibody were blocked
by incubation in the blocking solution GSDB (16.6% goat serum, 0.1% saponin, 20 mM Na-
phosphate pH 7.4, 450 mM NaCl) for 45 min at RT. The cells were then immunostained with
the primary antibody (in GSDB) for 2 hours at RT. The following antibodies were used: rabbit
α-ICA69 (215) (1:40); mouse α-GM130 (BD Transduction Laboratories) (1:25); α-TGN38 (BD
Transduction Laboratories) (1:25); mouse α-β-COP (clone maD) (Sigma Chemical Co.) (1:50);
mouse α-CPH (Transduction Laboratories) (1:500); mouse α-Synaptophysin (Synaptic System)
(1:1,000); rabbit α-p58 (or ERGIC) (gift from K.Svensson) (233) (1:50). After washing 3
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times with HS buffer, cells were incubated with α-mouse or α-rabbit, Alexa488- or Alexa568-
conjugated IgGs (Molecular Probes, Inc.) or with concavalin A, Alexa594-conjugated, in GSDB
(w/wo DAPI (Sigma Chemical Co.-Aldrich) to counterstain nuclei) for 1 hour at RT, and washed
3 times with HS buffer and twice with 120 mM Na-phosphate and mounted with ProLong Gold
antifade reagent (Molecular Probes, Inc.).
Images were acquired with a Zeiss Axioverted 200 M (inverted) confocal microscope (Carl
Zeiss, Inc.) and arranged using Adobe Photoshop 7 and Adobe Illustrator CS softwares.
6.9 Immunoprecipitation
Cells were washed twice with ice cold PBS and sedimented by centrifugation in the Heraeus
Multifuge centrifuge. The Triton X-100 soluble fraction was extracted by incubating the cells
in 800 µl (for a 175 cm2 flask 90% confluent) of immunoprecipitation (IP) lysis buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, 1% protease inhibitor cocktail) for 30 min
at 4 ◦C and centrifugation at 25, 000× g for 20 min at 4 ◦C in the centrifuge 5417R. The Triton
soluble fraction (750 µg of total protein were used for each IP) was then precleared with 100
µl of 50% ProteinA Sepharose 4 Fast Flow (Amersham Biosciences) or ProteinG Sepharose or
25% ProteinA/25% ProteinG Sepharose1 in PBS for 1.5 hour at 4 ◦C with shaking and beads
were then sedimented by centrifugation at 500× g for 6 min at 4 ◦C in the Heraeus Multifuge
centrifuge. A rabbit, mouse, goat or chicken antibody (10 or 20 µg, depending on the antibody)
was added to the precleared cell extract and the mixture was then incubated ON at 4 ◦C, with
rocking. The material was then washed 5 times with IP washing buffer (50 mM Tris-HCl pH
7.4, 300 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 0.02% Na-azide) and once with PBS at
4 ◦C. Beads were sedimented, bound material was eluted with SDS sample buffer (258) and
loaded on SDS-polyacrilamide gel.
6.10 Western blotting
Proteins were separated by 8-12% SDS-polyacrylamide Gel Electrophoresis (SDS-PAGE), trans-
ferred to nitrocellulose filters (Schleicher&Schuell BioScience GmbH), at 100 Volt (V) for 2 hours
or 40 mA ON, at 4 ◦C (258). Membranes were blocked with blocking solution (4% non fat dry
1The binding strenght of IgGs from various species to Protein G and protein A changes: Protein A and
Protein G was used in the IP with rabbit or mouse antibodies, Protein G was used in IP with goat antibodies.
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milk (AppliChem GmbH), 0.1% Tween-20 (MERK KGaA) in PBS) for 1 hour at RT, and
incubated with the primary antibody (in 3% Albumin fraction V (Carl Roth GmbH), 0.1%
Tween-20, 0.02% Na-azide in PBS) for 2 hours at RT or ON at 4 ◦C. The following antibod-
ies were used: rabbit α-ICA69 (226) (1:500); mouse α-ICA69 (1:150) (226); rabbit α-ICA69-
RP (described in section 6.13) (1:500); chicken α-ICA69-RP (GenWay Biotech, Inc.) (1:500);
mouse α-GM130 (BD Transduction Laboratories) (1:250); goat α-GFP (Protein Expression Fa-
cility / MPI-CBG, Dresden) (1:3,000); mouse α-GFP (Clontech Laboratories, Inc.) (1:1,000);
rabbit α-GST (Molecular Probes, Inc.) (1:2,000); mouse α-γ-tubulin (Sigma Chemical Co.)
(1:5,000); mouse α-Rabaptin4 (gift from M.Zerial) (1:1,000); mouse α-EEA1 (Transduction
Laboratories) (1:2500); mouse α-ICA512 (259) (1:75). After washing 3 times with the block-
ing solution, membranes were incubated with α-mouse or α-rabbit (Bio-Rad Laboratories) or
α-goat (Sigma Chemical Co.) or α-chicken (Jackson Immuno Research Laboratories, Inc.),
horseradish-peroxidase-coniugated (HRP-conjugated) IgGs in the blocking solution for 1 hour
at RT, washed twice with 0.1% Tween-20 in PBS and once with PBS.
Protein signals were detected by chemiluminescence with the Supersignal West Pico Sub-
strate (PIERCE Biotechnology, Inc.) or the Supersignal West Fempto Maximum Sensitivity
Substrate (PIERCE Biotechnology, Inc.) using a LAS-3000 Bioimaging System (Fuji) and
quantified with the Image Gauge v3.45 software (Fuji). Protein gels images were arranged
using Adobe Photoshop 7 and Adobe Illustrator CS softwares.
6.11 Expression of GST fusion proteins
Escherichia Coli cells, strain BL21, were transformed with the corresponding construct designed
to express a GST fusion proteins. A single colony was used to inoculate 50 ml of LB medium
(plus ampicillin 100 µg/ml) which was grown ON at 37 ◦C with shaking. The day after the cul-
ture was diluted to 1 l of LB medium plus ampicillin and grown at 37 ◦C with shaking until an
OD600 of 0.75, as measured in the spectrophotometer. Induction of GST-fusion protein expres-
sion was achieved by adding 0.5 mM final concentration of isopropyl-β-D-thiogalactopyranoside
(IPTG) (Sigma Chemical Co.) to the culture and incubating for 3 additional hours at 30 ◦C
with shaking. The cells were sedimented by centrifugation at 4,400 rpm for 20 min at 4 ◦C
in the Heraeus Multifuge centrifuge and then resuspended in 50 ml of PBS, containing 1%
protease inhibitor cocktail. The cell suspenction was sonicated 5× 20 sec with a 550 Sonic dis-
membrator (Fisher Scientific International, Inc.) and further homogenized with Triton X-100
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(Sigma Chemical Co.) for 30 min at 4 ◦C. The lysates were spun at 12,000 rpm for 30 min at
4 ◦C in an AvantiTM J20 (Beckman Coulter, Inc.) using a JA-25.50 rotor. The supernatant
was incubated with 1 ml of 50 % Glutathione Sepharose 4B (Amersham Biosciences) slurry,
pre-equilibrated with PBS, for 1.5 hours at 4 ◦C with rocking. Beads were sedimented by cen-
trifugation at 500× g for 6 min at 4 ◦C in the Heraeus Multifuge centrifuge and washed 3 times
with 10 beads volume ice-cold 0.1% Triton X-100 in PBS. Bound proteins were eluted from
the beads with 1.5 ml elution buffer (25 mM glutathione (Sigma Chemical Co.), 50 mM NaCl,
100 mM TRIS-HCl pH 8.0) (3 elution steps using 0.5 ml elution buffer, incubated for 15 min
with the beads, followed by sedimentation of the beads and recovery of the supernatant). The
protein solution was then dialyzed against PBS using Amicon Ultra centrifugal filter devices
(Millipore Corp.) with the appropriate molecular weight cut off (MWCO) .
The purity of the GST fusion protein was assessed by staining SDS-polyacrilamide gels with
Coomassie Brillant Blue R-250 (Bio-Rad Laboratories) (258).
6.12 GST pull down assay
75 µg of GST fusion protein (or GST) were used for each pull down assay. The GST fusion
protein was incubated with 100 µl of 50 % Glutathione Sepharose 4B in PBS for 1.5 hours at
4 ◦C with shaking; beads were sedimented by centrifugation at 500× g for 6 min at 4 ◦C in the
centrifuge 5417R and washed once with 10 beads volume ice-cold 0.1% Triton X-100 in PBS.
To determine the yield of the procedure, the bound GST fusion protein was eluted with SDS
sample buffer containing dithiothreitol (DTT) (New England Biolabs, Inc.-NEB) (258). 1/20
of the eluted material was loaded on SDS-polyacrilamide gel and compared by Coomassie Bril-
lant Blue staining of the gel with the GST fusion protein used to load the beads (1/20 of the
amount of protein used to load the beads). The GST fusion protein immobilized with the
beads was then loaded with GTPγS (or GDP), as described in (245). Briefly, the material
was washed with 500 µl of nucleotide exchange buffer (NE buffer) containing 20 mM HEPES,
100 mM NaCl, 10 mM EDTA, 5 mM MgCl2, 1 mM DTT, 10 µM GTPγS (Guanosine-5’-O-(3-
thiotriphosphate)Tetralitium salt) (Sigma Chemical Co.) (or GDP (Guanosine-5’-diphosphate
sodium salt) (Sigma Chemical Co.)), pH 7.5, and then incubated with 200 µl NE buffer con-
taining 1 mM GTPγS (or GDP) for 30 min at RT under rotation. Afterwards, NE buffer was
removed and the wash and incubation procedure described above was repeated once more. The
material was then washed with 500 µl of nucleotide stabilization buffer (NS buffer) containing
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20 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10 µM GTPγS (or GDP), pH 7.5,
and further incubated with 100 µl NS buffer containing 1 mM GTPγS (or GDP) for 20 min at
RT under rotation.
Triton X-100 soluble fractions of INS-1 cells were prepared as described above. The cell
extract was then dialyzed against NS buffer in the absence of the nucleotide, precleared with
200 µl of 50 % Glutathione Sepharose 4B in PBS for 45 min at 4 ◦C with rocking, and then
quantified as described above. 750 µg of total protein were used for each pull down.
GST fusion protein immobilized to the beads were incubated with the cell extracts for 10
hours at 4 ◦C with rocking in presence of 100 µM GTPγS (or GDP). The material was then
washed with 500 µl of NS buffer containing 10 µM GTPγS (or GDP), 500 µl of NS buffer
containing 250 mM NaCl final concentration and 10 µM GTPγS (or GDP), and then with
200 µl wash buffer 3 containing 20 mM HEPES, 250 mM NaCl, 1 mM DTT, pH 7.5. Beads
were sedimented, bound material was eluted with SDS sample buffer (258) and loaded on SDS-
polyacrilamide gel.
When GST alone was used for the pull down assay, the material was prepared exactly as
described above, but neither GTPγS nor GDP were present in the buffers.
6.13 Production of an α-ICA69-RP antibody
RPantigen-GST was expressed in BL21 as described above and dialized against PBS. 3.3 mg
of RPantigen were sent to Eurogentec (EGT Group) in order to immunize 2 rabbits, with
100 µg antigen per injection and per animal. The standard protocol offered by Eurogentec
was applied; briefly: 1 ml volume per injection (500 µl antigen solution, 500 µl adjuvant);
injections: days 0, 14, 28, 28 +n28 (with n = 1, 2, 3 . . . ) (standard injection way: intradermic
multisite); bleedings: days 0 (preimmune, 2 ml), 38 (2 ml), 53 (20 ml), 53 + n15 (20 ml)
. . . day 320 final bleeding. The bleeds were tested by ICC and WB and purified by affinity
chromatography. The chromatographic column was loaded with RPantigen, obtained from
RPantigen-GST still loaded on the Glutathione Sepharose 4B (see above) after cleavage for 16
hours at RT with 100 units of Thrombin Protease (Amersham Biosciences). Thrombin was then
removed using an HiTrap Benzamidine FF (high sub) column (Amersham Biosciences). The
affinity chromatography was performed using an AminoLink R© kit (PIERCE Biotechnology,
Inc.) according to the manufacturer’s recommendations. The fractions of interest, as assessed
by reading their absorbance at 280 nm, were pooled and dialyzed against 0.02 % Na-azide in
108
6.14 Protein-lipid overlay assay
PBS using a Slide-A-Lyzer R© Dialysis Cassette (PIERCE Biotechnology, Inc.), 3.5 MWCO. The
antibody was then aliquoted and stored at 4 ◦C.
6.14 Protein-lipid overlay assay
Phospolipid-spotted nitrocellulose membranes (PIP strips, Molecular Probes, Inc.) were blocked
in 3% Albumin fraction V in 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween-20 (TBS-T).
The membranes were incubated with 1 µg/ml GST, ICA69-GST or Amphyphisyn-GST in the
blocking solution ON at 4 ◦C. The day after membranes were washed 3 times with the blocking
solution. Thereafter the detection of bound proteins was performed by western blotting, as
indicated above, using a rabbit α-GST (Molecular Probes, Inc.) (1:2,000).
6.15 Sequence alignment
Multiple sequence alignment and genealogical tree were produced with the program ClustalW
(http://www.ebi.ac.uk/clustalw/); the alignments were manually refined manually.
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Appendix A
ICA69 and ICA69-RP family:
sequence alignment
Multiple sequence alignment (on the next page) of ICA69 protein family in humans, mice
and rats, generated using ClustalW, a multiple sequence alignment program, at the European
Bioinformatic institute (EBI). The BAR domain encompasses the region at the N-terminus,
where the three helixes are positioned. The cyan rectangles (both at the C-terminus and at
the N-terminus) indicate regions of high homology within the family members. Colors-code:
red: small; blue: acidic; magenta: basic; green: Hydroxyl + Amine + Basic - Q. At the
bottom of the sequence, “?” indicates residues identical in all the sequences in the alignment;
“:” indicates conserved substitution, according to the colors-code indicated above; “.” indicates
a semi-conserved substitution. Accession numbers (NCBI): H.sapiens ICA69: NP 071682.1;
M.musculus ICA69: NP 034622.2; R.norvegicus ICA69: NP 110471.1; H.sapiens ICA69-RP:
NP 612477.3; M.musculus ICA69-RP: NP 081683.2; R.norvegicus ICA69-RP.
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 Ø = not transfected
GFP = transfected with pEGFP-N1















































Figure B.1: Specificity of the α-ICA69 antibody
As a strong homology at the protein level exists between ICA69 and ICA69-RP, it was pos-
sible that the antibodies against ICA69 did crossreact with ICA69-RP. To test this hypothesis
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Triton X-100 soluble fraction was prepared from HEK cells and HEK cells overexpressing GFP
or ICA69-RP-GFP, followed by SDS/PAGE and western blotting with the antibodies indicated
in Fig. B.1, on the top. The α-ICA69 antibody does not detect the endogenous ICA69 (Fig. B.1,
lanes 2 and 4), as in this cell line the amount of the protein is negligible (215). The same anti-
body does not recognize ICA69-RP-GFP (Fig. B.1, lane 6), which is instead recognized by both
the α-GFP and α-ICA69-RP antibodies (Fig. B.1, lanes 11 and 12). Therefore the polyclonal
antibody against ICA69 does not crossreact with ICA69-RP. The figure is relative to the poly-
clonal α-ICA69, which was raised against residues 471-483 of human ICA69. Identical results
were obtained with a monoclonal antibody, which recognize an epitope in the first 230 amino


















Figure B.2: Purification of ICA69-RP-antigen in fusion with GST
In order to obtain α-ICA69-RP specific antibodies a construct expressing a fusion protein
between GST and the amino acids 266-402 of ICA69-RP (and termed ICA69-RP-antigen) was
generated. The construct was expressed in bacteria and the corresponding GST-fusion protein
purified. Fig. B.2 A shows a Comassie Brillant Blue-stained protein gel for bacterial extracts
in which the expression of ICA69-RP-antigen has been induced (lane 1) and ICA69-RP-antigen
after purification and dialysis (lane 2). Fig. B.2 B shows a western blotting, on an identical gel,
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obtained with an α-GST antibody. The arrows point, in both cases, to the expected molecular























GFP = transfected with pEGFP-N1
RP = transfected with pEGFP-ICA69-RP
GFP
WB
GFP GFP GFPRP RP RP RP
Figure B.3: Specificity of sera for ICA69-RP
In the production of α-ICA69-RP specific antibodies, the reactivity of the crude rabbit
antisera was tested by evaluating its reactivity against a fusion protein between ICA69-RP and
the green fluorescent protein (GFP). Fig. B.3 shows a western blotting on HEK cells Triton
X-100 soluble fractions with an α-GFP antibody, with preimmune serum from two different
rabbits (indicated as pre.r1 and pre.r2, respectively), or with serum from the same rabbits after
immunization against the ICA69-RP-antigen; the cells were either transfected with pEGFP-N1,
as a negative control, or with pEGFP-ICA69-RP. ICA69-RP-GFP is detected at the expected
molecular weight of ∼80 kDa protein, with the α-GFP antibody and with the sera from the
immunized rabbits, but not with the pre-immune sera from the same animals.
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